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ARGUMENT
I.

DR. CHAMBERLAIN HAS FAILED TO OFFER ANY SUPPORT FOR HIS
ASSERTION THAT AN EXPERT CANNOT VIEW CONFIDENTIAL
INFORMATION UNDER § 78-14-12(l)(d).
As set forth in Munson's Opening Brief, Munson's principal assertion is that

regardless of whether the prelitigation documents in question are or are not confidential
under Utah Code Annotated § 78-14-12(l)(d), an expert witness like Dr. Jacobs is already
within the category of non-public persons who can view such confidential documents without
violating any statutory proscription. See generally Munson Opening Br. at pp. 8-20. In his
responsive brief, Dr. Chamberlain has failed to directly rebut this central and dispositive
contention.
First, Dr. Chamberlain has filed to cite to any statutory language from §78-14-12, the
Utah Health Care Malpractice Act, any related Utah statute, or even any non-related Utah
statute that prevents experts from viewing any confidential information in any litigation
setting.
Second, Dr. Chamberlain has failed to cite to any legislative history from § 78-14-12
or from the Utah Health Care Malpractice Act that in any way indicates that the Legislature
intended to prevent parties from providing the prelitigation documents to their own retained
experts.
Third, Dr. Chamberlain has failed to cite to any decision interpreting either Utah Code
Annotated § 78-14-12 or any other provision from the Utah Health Care Malpractice Act so
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as to contain such a prohibition. At most, Dr. Chamberlain has repeated his bare assertion
that the decision of the Utah Supreme Court in Doe v. Maret, 1999 UT 74, 984 P.2d 980,
somehow compels this result. Doe v. Maret does not, however, indicate that a violation of
§ 78-14-12 occurred here. As discussed at lenglh in Munson's Opening Brief, see Munson's
Opening Br. at pp.9-10, 19-20, Doe merely held that § 78-14-12(l)(d) is violated when a
party quotes from and attaches a prelitigation document to a publicly filed appellate brief.
Doe, 1999 UT 74 at ^[21. Doe said absolutely nothing about non-public disclosures being
prohibited under the statute, nor did the decision in any way state, indicate, or even imply that
a private disclosure of a party's own documents to that party's own retained expert witness
is in any way prohibited by the statute. Dr. Chamberlain's assertion that Doe prohibited the
disclosure that occurred here is manifestly incorrect.
Given the total absence of any Utah authority prohibiting the disclosures that occurred
here, the only way the trial court's decision would be supportable is if Dr. Chamberlain had
offered authority from other jurisdictions interpreting the term "confidential" in a way that
prevented experts from viewing information in a case-which would at least make it arguable
that the Legislature intended such a result under § 78-14-12(l)(d). Such citation would have
been particularly necessary given Munson's extensive citation in her own brief to cases
holding (1) that experts play a vital and necessary role in modern litigation, and (2) that as
a result, experts must be deemed authorized to view any information that is deemed
confidential in a case. See Munson's Opening Br. at pp. 12-19. Rather than citing to any
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contrary authority, however, Dr. Chamberlain instead simply attempts to distinguish these
cases by noting that most of them involved protective orders. Dr. Chamberlain's Br. at p. 31
n. 11. This argument presents the classic distinction without a difference. Protective orders
were necessary in the cited cases in order to first impose a confidentiality status on the
information in question, and to then dictate the terms by which that confidential information
would be used throughout discovery and trial. Here, the information in question has already
been legislatively and judicially deemed confidential under § 78-14-12(l)(d) and Doe v.
Maret so no protective order was needed to accomplish this end. The relevance of the cited
authority therefore had nothing to do with the protective order classification aspect, but rather
with the fact that under each of these orders, all expert witnesses were allowed access to the
confidential information. This extensive list of authority at the very least supports Munson's
assertion that, at common law, it is routinely and uniformly assumed that an expert witness
can view information or documents that have been deemed "confidential." Given that the
Legislature is presumed to use statutory terms "advisedly," Dr. Chamberlain's Br. at p. 29
(quoting Salt Lake Child & Family Therapy Clinic. Inc. v. Frederick, 890 P.2d 1017, 1020
(Utah 1995)), this cited authority strongly supports the conclusion that the Legislature did not
intend to keep experts out of the loop in medical malpractice cases. Dr. Chamberlain has
simply failed to offer any authority showing any circumstance where the term "confidential"
was interpreted any differently.
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It is not enough for Dr. Chamberlain to simply note that § 78-14-12 renders the
information in question "confidential" and leave it at that. Instead, given Munson's
extensive citations to authority on the meaning of this exact term, Dr. Chamberlain needed
to respond by somehow demonstrating that the term "confidential'" in this context actually
prohibited the conduct in question. None of his cases or arguments stand for such a
proposition. As such, this Court should conclude that the term "confidential" in § 78-14-12
means what it always means, and that violations of the statute only occur when unauthorized
members of the public are granted access to the protected information. Dr. Jacobs was not
a member of the public when he received these documents, and he was expressly authorized
to view the documents by virtue of his status as a retained expert witness. Dr. Chamberlain
has offered no authority that would compel a contrary result.
11.

DR. CHAMBERLAIN'S ATTEMPT TO OVERRULE DOE v. MARET BY WAY
OF DISTINCTION SHOULD BE REJECTED BY THIS COURT.
Rather than addressing the question of experts and confidentiality head-on, Dr.

Chamberlain instead attempts to create a violation in this case by asking this Court to
distinguish Doe v. Maret on a number of specific levels. First, Dr. Chamberlain asks this
Court to draw a distinction between consulting experts and testifying experts, thereby holding
that only consulting experts can be given access to confidential information under § 78-1412. Second, Dr. Chamberlain asks this Court to draw a distinction between documents that
were prepared for the prelitigation panel and those documents that were simply submitted to
the prelitigation panel.
Page 4 of 24
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As an initial matter, it should be pointed out that while Dr, Chamberlain couches this
as being a "failure [on Munson's part] to draw three key distinctions," Dr. Chamberlain's Br.
at p. 9, Dr. Chamberlain fails to acknowledge that none of these distinctions have actually
been drawn in any Utah cases. While this Court certainly has the power to draw such
distinctions if they are not contrary to prior precedent, the suggestion that Munson has
somehow "failed" by not drawing distinctions that do not actually exist seems strained at
best.1
Regardless, a closer look at Chamberlain's suggested distinctions shows that not only
are they each unsupported under current law, but also that each would have no substantive
bearing on the outcome of this case even if they were accepted by this Court.
A.

The distinction between consulting and testifying experts is not relevant to
the actual issues presented and should not be created nor applied by this Court
in this case.

The first distinction that Dr. Chamberlain asks this Court to draw is between
consulting experts and testifying experts. Specifically, Dr. Chamberlain argues that while
consulting experts should be allowed to view prelitigation materials under the § 78-1412/Doe confidentiality scheme, experts who will be called to testify cannot be allowed to

'This suggestion is further puzzling insofar as Dr. Chamberlain has himself asked this
Court to reject Munson's own interpretation of § 78-14-12, in large part arguing that this
Court should not adopt any interpretations that move beyond the strict terms of Doe. See Dr.
Chamberlain's Br. at p. 18 (arguing that "this Court lacks the authority to overturn Maret,"
and quoting case law for the position that "[o]nly the Utah Supreme Court can correct any
deficiencies in [its precedent]").
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view such materials because they may ultimately be subjected to a public cross-examination
regarding the documents they have viewed.
As an initial matter, it should be pointed out that neither §78-14-12 nor Doe v. Maret
says anything about expert witnesses at all, let alone there being some distinction between
consulting and testifying experts. Dr. Chamberlain therefore creates this distinction for
purposes of this appeal. In addition to being unsupported by current law, however, this
distinction is also contrary to common practice under Utah's litigation rules. Under the rules
of procedure, parties are not required to even make a preliminary determination regarding
which witnesses will or will not be called to testify until thirty days after the expiration of
fact discovery. See Utah Rule of Civil Procedure R. 26(a)(3)(C). If the testifying/consulting
expert distinction put forward by Dr. Chamberlain were adopted, however, a party would
have to make this determination with respect to each prospective expert prior to having even
discussing the case with that expert in their initial consultations. Otherwise, the party would
run the risk of inadvertently disqualifying the expert from participation at trial by providing
the expert with the wrong type of information at the outset. If adopted, Dr. Chamberlain's
seemingly innocuous distinction would dramatically alter the way that experts are used in
medical malpractice litigation, with this sea-change not being mandated by any statute, or any
rule, or any case dealing with the Utah Health Malpractice Act.
Dr. Chamberlain's application of this particular distinction to this case is ultimately
striking, however, insofar as it represents a key admission on Dr. Chamberlain's part.
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Specifically, by asserting that consulting experts are allowed to view prelitigation materials
without violating the confidentiality requirement of § 78-14-12, Dr. Chamberlain is
effectively conceding that the confidentiality requirement does not absolutely bar subsequent
disclosure of prelitigation documents to any and all persons. Instead, his argument is that
under both § 78-14-12(l)(d) and Doe v. Maret disclosure to an expert is only impermissible
if the expert is going to eventually testify at trial.
The problem with this argument is that it approaches the question on appeal in a
manner that is analytically backwards. Rather than directly addressing the question of
whether a party is authorized to disclose prelitigation materials to its own expert, the
argument instead focuses on the subsequent consequences of the other party later wanting
to conduct a public cross-examination regarding that disclosure. As discussed on pages 2026 of Munson's Opening Brief, however, this circular, imputation-based argument is based
on at least three false premises.
The first false premise is that such a cross-examination would have necessarily
violated the confidentiality requirement of §78-14-12. As noted in Munson's Opening Brief,
however, this cross-examination could have been conducted in a non-public, sealed setting,
thereby preserving the confidentiality of the information. These sort of confidentialityprotective procedures are routinely employed, as evidenced by the protective order cases
cited by Munson in her Opening Brief. In such cases, confidential information is routinely
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discussed and put before a trier of fact without in any way exposing that information to the
general public.2
The second false premise is that a party's inability to cross-examine an opposing
witness about all possible sources of bias is somehow problematic as a matter of law. A
party does not always have an absolute right to cross-examine a witness about all possible
subjects. Even where relevant, some subjects are simply excluded from cross-examination
due to a variety of more compelling reasons (such as the exclusionary rule, an applicable
confidentiality requirement, or a protective order). Thus, even if it were the case that this
whole subject were off limits and the cross-examination could not occur at all, this
prohibition still would have no impact on Dr. Chamberlain's rights in a way that is in any
way unique or unfair.3
2

Dr. Chamberlain's particular assertion that a closed, non-public examination would
still not be possible because of § 78-14-12's prohibition on introducing evidence regarding
the prelitigation "proceedings," Dr. Chamberlain's Br. at p. 26 n.7, is likewise flawed. As
discussed throughout his brief, Dr. Chamberlain simply wants to cross-examine Dr. Jacobs
regarding the impact of these documents on Dr. Jacobs' thinking. Given this limited scope,
it is difficult to understand how this cross-examination would have involved a discussion of
the "proceedings" of the prelitigation panel at all. Such an examination would not have
required discussion of prelitigation testimony, the nature of the panel's deliberations, or the
terms of, let alone the existence of, the panel's actual decision. In all reality, there would
have been no need to mention that the panel even existed to have conducted a thorough
examination on this point.
3

Dr. Chamberlain's related argument that preventing him from conducting such a
cross-examination would violate Rule 26 of the Utah Rules of Civil Procedure is unfounded.
Dr. Chamberlain's Br. at p. 25-26. As noted by Dr. Chamberlain in his brief, Rule 26 simply
requires an expert to provide a "summary of the grounds" for each of his opinions, but says
nothing about requiring disclosure of everything that a witness has ever viewed that has any
remote connection to a case. At the end of Dr. Jacobs' deposition testimony in this case, he
Page 8 of 24
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The third false premise is that a ruling preventing Dr. Chamberlain from crossexamining Dr. Jacobs regarding his knowledge of the prelitigation documents would have
had any substantive impact on this case at all. During the discovery phase of this case, Dr.
Jacobs was deposed by Dr. Chamberlain's counsel. The full text of that sworn deposition
is attached as an addendum to this brief (and is located in the record at pp. 395-77). During
that deposition, Dr. Jacobs was able to offer detailed, fact-based support for each of his
opinions in this case, and in spite of the extensive questioning, he was never forced to
"parrot" or even refer to the opinions of Dr. Kane or the Notice of Intent. See Addendum,
deposition pp. 22-72.
Regardless, this whole cross-examination based argument is ultimately diversionary.
Specifically, this argument is focused on the consequences of a confidentiality breach that
Dr. Chamberlain wants to commit, and not on the question of whether Munson actually
committed a violation of her own. Contrary to Dr. Chamberlain's assertions, the question
at issue here is not how to cross-examine an expert regarding these matters. Rather, the
question is simply whether an expert is allowed to view these materials at all in the first
instance. Dr. Chamberlain simply should not be allowed to impute the consequences of his
own hypothetical violations onto Munson, and this Court should decline the invitation to be

specifically stated that he had disclosed and discussed all the bases and grounds for his
opinion. R. at 378, deposition p. 71. The obvious meaning of this direct statement is that
though Dr. Jacobs may have viewed other documents or had other conversations relating to
this case, none of those had any bearing on his opinions. As such, Munson's Rule 26
obligations were fully satisfied.
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distracted from the actual legal question at issue by focusing on this non-existent distinction.
The question here is whether a retained expert is allowed to view the confidential information
under § 78-14-12 or Doe v. Maret. Dr. Chamberlain's focus on the subsequent effects of
such a disclosure shoots beyond the mark of this question entirely.
B.

Dr. Chamberlain's argument that there is a distinction between documents
that were prepared for the prelitigation panel and those that were simply
submitted to the panel is contrary to the express language of Doe v. Maret and
should be rejected.

Dr. Chamberlain argues that there is a distinction between documents that are
"specifically prepared for the prelitigation panel" (hereinafter "prelitigation documents") and
documents that only reflect "the underlying facts of the case" (hereinafter "evidentiary
documents"). Dr. Chamberlain Br. at p. 21. According to Dr. Chamberlain, while the
prelitigation documents are "confidential" under § 78-14-12, the evidentiary documents are
not. By drawing this distinction, Dr. Chamberlain asserts that the absurd result of experts not
being allowed to view such documents as medical records can be avoided.
The chief problem with drawing this distinction, however, is that it still doesn't solve
the problem of this case. Specifically, regardless of whether all documents are deemed to be
confidential under § 78-14-12, or whether it is only the prelitigation documents that are
deemed to be confidential, Munson has still argued that experts are entitled to view all
confidential documents relating to a case under both § 78-14-12 and the general law of
confidentiality. Thus, even if accepted, this proposed distinction literally has no bearing on
Munson's argument.
Page 10 of 24
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Even if this distinction did have some bearing on this case, however, Dr.
Chamberlain's attempt to draw and enforce it here should be rejected because the distinction
is expressly contrary to the plain language of the Utah Supreme Court in Doe v. Maret
Contrary to Dr. Chamberlain's assertions, the Supreme Court did not hold that documents
are deemed confidential if they are "prepared for and submitted to the prelitigation panel."
Dr. Chamberlain's Br. at p. 19. Dr. Chamberlain's assertion otherwise is simply wrong,
insofar as the term "prepared for" does not appear anywhere in the Utah Supreme Court's
opinion. See 1999 UT 74 at | 2 1 . Instead, the full text of the court's analysis of the
confidentiality question is as follows: "Today we hold that because the notice of intent serves
as the basis for the prelitigation panel review, and because it is often utilized as part of the
prelitigation review, it is part of the proceeding and must be kept confidential." Id.
Given this plain statement, Dr. Chamberlain's suggestion that a document (such as a
medical record) that "served as the basis for the prelitigation panel review" and which was
"utilized as part of the prelitigation review" could somehow be rendered non-confidential
simply because it was factual or evidentiary in nature is expressly contrary to the plain terms
of Doe. Dr. Chamberlain's suggested distinction therefore isn't really a distinction at all, but
is in reality a disguised attempt to overturn Doe's core premise. While Munson certainly
agrees that the Doe framework should be revised by the Supreme Court if necessary on
certiorari review, see Munson's Opening Brief at pp. 32-34, Dr. Chamberlain's attempt to
have this Court accomplish this task at this stage is at best self-contradictory. See Dr.
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Chamberlain's Br. at p. 18 (arguing that "this Court lacks the authority to overturn Maret,"
and quoting case law for the position that "[o]nly the Utah Supreme Court can correct any
deficiencies in [its precedent]"). So long as Doe is binding, this Court must accept Doe's
assertion that documents that "served as the basis for the panel review" and which were
"utilized" by the panel are confidential.
It is for this reason that Munson's waiver argument is so crucial in understanding the
medical malpractice scheme created by Doe. Medical records have long been deemed to be
both "privileged" and "confidential" under the law. See, e.g.. People v. Caballes, 851
N.E.2d 26, 51 (111. 2006) (noting that "the confidentiality of personal medical information
is, without question, at the core of what society regards as a fundamental component of
individual privacy"); State v. Demarav. 704 N.W.2d 60,66 (Iowa 2005); Statev.Blom, 682
N.W.2d 578, 617 (Minn. 2004); Jones v. Asheville Radiological Group, P.A., 500 S.E. 2d
740, 745-46 (N.C. App. 1998). Indeed, these protections are now codified under the federal
HIPPA statute. In spite of this, courts have routinely held that patients waive such privileges
or confidentiality protections by choosing to file a medical malpractice lawsuit. See, e.g.
Jones, 500 S.E. 2d at 745-46; Great West Life Assur. Co. v. Levithan, 153 F.R.D. 74, 77
(E.D.Pa. 1994).
In this context, § 78-14-12 says that the "proceedings" of the prelitigation panel are
confidential, and Doe expressly extends that protection to the documents that were "utilized"
and "relied" on by the panel. Doe's protections of these documents are presumably for the
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plaintiff as much as for the defendant, insofar as the plaintiffs notice of intent or medical
records may contain details that are sensitive to the plaintiff. Thus, what Doe ostensibly does
is bring harmony to the prelitigation panel's confidentiality rule. Without Doe, a plaintiff
would theoretically waive her medical privacy rights (at least vis a vis her medical records)
by submitting her case to a prelitigation panel. Under Doe, however, the confidentiality
protections afforded to her medical records continue through the prelitigation process, and
waiver still only occurs if the plaintiff actually takes the next step and initiates a public
lawsuit.
This case therefore stands in stark contrast to the disclosure that was at issue in Doe.
In Doe, the defendant doctors had tried using the plaintiffs prelitigation materials against
her. 1999 UT 74 at <pi. Here, however, Munson is charged with having used her own
documents to support her own case. Whatever confidentiality protections do or do not attach
to such documents, Munson should be granted the right to use her own documents and
medical records in any manner that she sees fit. Neither § 78-14-12 nor Doe says anything
to the contrary.
Dr. Chamberlain responds by asserting that by submitting her medical records or
expert reports to the prelitigation panel, Munson has given control over that privilege to the
Utah State Legislature. Chamberlain's Br. at pp. 28. Not only is this assertion of Legislative
control not supported by authority, but it is also a non-issue in the context of this particular
case. The privilege asserted by the Legislature in § 78-14-12 is over the prelitigation panel's
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proceedings, not the documents submitted to the panel. Here, no party has requested
permission to in any way discuss or refer to the panel or to its proceedings. All that is at
issue is certain documents (prepared by a party, not the panel) which happen to have been
submitted to the panel. While Munson certainly cannot waive the protections afforded by
the Legislature to the panel's proceedings, there is no reason that she cannot waive any
protections that have attached to her own documents by her own choice to submit them to the
panel in support of her own case.
Regardless, as noted above, this entire analytical discussion is, like Dr. Chamberlain's
other distinction-based arguments, ultimately diversionary. The basis for Munson's appeal
is that regardless of whether the documents are or not deemed to be under the § 78-14-12
confidentiality umbrella, her expert witnesses are deemed qualified to view all such
documents. There is nothing in Doe or § 78-14-12 that compels a contrary result, and the
purported distinction between prelitigation and evidentiary documents does not change this
result either. Rather than drawing the unnecessary and ultimately inapplicable distinction
between prelitigation and evidentiary documents, Munson instead respectfully suggests that
this Court follow Doe as written and not try to distinguish it into something new. Doe
expressly stated that prelitigation materials are confidential, and then stated that sanctions
could be imposed in a case where a party had attached such materials to a publicly filed brief.
The trial court in this case took this ruling a step further and held that private disclosure to
a party's own retained expert is also sanctionable. The trial court's ruling on that discrete
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question can and should be overturned without violating, distinguishing, or challenging Doe
in any way.
III.

THIS COURT SHOULD REJECT DR. CHAMBERLAIN'S ATTEMPT TO
OBTAIN A MORE FAVORABLE STANDARD OF REVIEW BY CREATING
CONFUSION REGARDING THE RULINGS AND ARGUMENTS ON APPEAL.
Finally, Dr. Chamberlain spends much of his brief describing how confused he

apparently is regarding the nature of this appeal. Dr. Chamberlain specifically claims that
he is confused regarding (1) which ruling is being appealed from, and (2) what issues were
actually raised in Munson's Opening Brief. Both sources of confusion share a significant
common characteristic: namely, if accepted by this Court, both would result in this case being
reviewed under the more deferential abuse of discretion standard of review. Rather than
accepting Dr. Chamberlain's invitation to afford him such an unearned benefit, however, this
Court should instead conclude that neither of the confusion based arguments has merit.
A.

There is no valid basis for Dr. Chamberlain to claim confusion over which
ruling is at issue.

Dr. Chamberlain first claims that he is confused over which ruling is being appealed.
See Dr. Chamberlain Br. at pp. 1-2. This claim of confusion should be ignored, however,
because Munson's Opening Brief was in fact quite clear regarding which rulings are at issue.
On page 1 of Munson's Opening Brief, she succinctly stated that "there are two rulings at
issue in this appeal," and then identified those rulings as being (1) the mistrial ruling, and (2)
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the summary judgment ruling. IdL4 At the beginning of her Argument section, Munson
repeated this assertion, again stating that the summary judgment ruling and the mistrial
rulings are the two rulings at issue. L± at 8 n.4. Munson reiterated this in her Conclusion
section, wherein she requested that this Court "overturn the order of mistrial and the grant
of summary judgment." Munson's Opening Br. at p. 35. Indeed, while the terms "summary
judgment" and "mistrial" were used throughout the brief, the terms "reconsider" and
"reconsideration" do not appear anywhere in the Statement of the Issues, the Summary of the
Argument, the Argument, or the Conclusion sections of Munson's Opening Brief. Thus,
other than passing references to the reconsideration motion in the Statement of the Case,
there is literally nothing in Munson's Opening Brief that indicates that that motion is in any
way being placed at issue.
Dr. Chamberlain actually admits in his own brief that he fully understands that
Munson's argument is focused on the summary judgment and mistrial rulings. On page 2 of
his brief, Dr. Chamberlain acknowledges that the mistrial ruling was "the focus of the
opening brief." Similarly, on page 8, Dr. Chamberlain notes that the mistrial and summary
judgment rulings are the "rulings at issue." On page 9 he notes that Munson had "argue[d]
that Judge Davis incorrectly ruled she had breached the confidentiality of the prelitigation
proceedings," and on page 14 he states that it "is clear in the opening brief [ ] that Ms.

4

As was explained on page 8 n. 4 of Munson's Opening Brief, these two rulings were
expressly predicated on the same erroneous conclusion of law, and have therefore been
addressed together throughout this appeal.
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Munson's primary contention now is that Judge Davis erred by ordering a mistrial." In light
of this, his confusion-based attempt to gain a more favorable standard of review should be
rejected.5
B.

This Court should hold that the Notice of Appeal that was filed in this case
provided sufficient notice that the summary judgment and mistrial rulings
would be appealed.

Dr. Chamberlain next argues that the Notice of Appeal that was filed in this case
should be construed so as to limit this appeal to an analysis of the Motion for
Reconsideration. This argument should be rejected by this Court for two different reasons.
First, Utah law allows an appellate court to overlook an error in the Notice of Appeal
as long as that error is not one of timeliness. "Despite the apparent rigidity of rule 3(d) of
the Utah Rules of Appellate Procedure, 'notices of appeal are to be liberally construed,'" and
a notice of appeal may therefore be deemed "adequate even if it does not strictly adhere to
the requirements of rule 3(d)." State v. Valdovinos. 2003 UT App 432,ffl[17,18, 82 P.3d
1167. As long as the Notice of Appeal "sufficiently notifies" a party of the issues that are
going to be appealed, clerical mistakes within the Notice of Appeal (such as misidentification
of the parties or the rulings) simply do not limit a court's ability to consider the rulings that
were placed at issue in the actual brief. InreB.B., 2004 UT 39, f 10, 94 P.3d 252.

5

Dr. Chamberlain's additional reference to the Docketing Statement as being support
for his confusion should be rejected, because the Utah Supreme Court has held that the issue
designations in a docketing statement have no bearing on a party's right to subsequently raise
different issues in the appellate brief itself. See Nelson v. Salt Lake City, 919 P.2d 568, 572
(Utah 1996).
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This principle was made plain by the recent decision of the Utah Supreme Court in
Davis v. Central Utah Counseling Center, 2006 UT 52, -P.3d-. In Davis, the Court held that
"the timely filing of a notice of appeal is the only jurisdictional requirement for appellate
review," and that "[e]ven where an appellant files a notice 'crippled with defects' and fails
to effectively serve the opposing party, the notice is jurisdictionally sufficient if it complies
with the timeliness requirement." Id. at <|fl4. This Court's decision in State v. Valdovinos
is likewise applicable. In Valdovinos, this Court considered a case like this one where the
notice of appeal referred to a different ruling than the ruling which was later addressed in the
brief. Rather than allowing this mistake to limit the scope of the appeal, however, this Court
instead considered the appeal as it was briefed, due in large part to the appellee's failure to
show that it was prejudiced by the misidentification in the notice of appeal. 2003 UT App
432 at Tf20. Here, not only does Dr. Chamberlain openly acknowledge that Munson's
arguments on appeal are directed at the summary judgment and mistrial rulings, but he then
fully briefs his position with respect to those two rulings. As such, the misidentification in
this Notice of Appeal was non-prejudicial and should not serve as the basis for limiting the
scope of this appeal.
Second, consistent with the "sufficient notice" standard referenced above, it is wellaccepted that where multiple rulings are intertwined, a notice of appeal that references one
of those rulings provides a proper basis for reviewing the others. In Valdovinos, this Court
considered a Defendant's appeal from a sentencing decision. Though the sentencing had
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been based on guilty pleas in three separate criminal cases, the notice of appeal only
referenced one of those three cases. Id. at 1HP-7, 8 n.l. In spite of this error, this Court
allowed the appeal of all three rulings to proceed, explaining that the three rulings were
sufficiently intertwined so as to warrant consideration of all the rulings. Specifically, this
Court held that sufficient notice had been provided because the three rulings had all been
argued in "one consolidated hearing" and had been ruled on "on the same date." Id at ^J20.
A similar result was reached under similar circumstances in In re B.B., wherein the Utah
Supreme Court allowed a ruling to be considered on appeal even though a different ruling
had been identified in the notice of appeal. As in Valdovinos, the court in InreB.B. noted
that the two rulings had been argued and decided on the same date, and the court therefore
considered the non-identified ruling on appeal. 2002 UT App 82 at Tfl 1.
As in Valdovinos and In re B.B., the summary judgment motion and the motion for
reconsideration were briefed concurrently, argued in the same hearing, and ruled on in the
same written order that was issued on the same date. These two particular motions are
additionally intertwined insofar as Munson expressly incorporated the reconsideration
motion into her response to the summary judgment motion. R. at 398-397. Judge Pullan
acknowledged this link in his ruling, holding that Dr. Jacobs was disqualified "based upon
[the] denial of the Motion to Reconsider," and that summary judgment was therefore proper
only because of this disqualification. R. at 544. As such, Dr. Chamberlain clearly had
^sufficient notice" that both the summary judgment ruling and the mistrial ruling were at
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issue when the Notice of Appeal listed the reconsideration motion as being the basis for the
appeal.
In Scudder v. Kennecott Copper Corp., 886 P.2d 48 (Utah 1994), the Utah Supreme
Court held that "[w]hen appealing from an entire final judgment, . . . it is not necessary to
specify each interlocutory order of which the appellant seeks review.5' Id. at 50. Thus,
because the summary judgment ruling is properly at issue here, all prior rulings-including
the mistrial ruling-are properly at issue as well. Dr. Chamberlain's argument that the appeal
should be limited to the reconsideration motion should be rejected.
C.

There is no valid basis for Dr. Chamberlain to claim confusion over which
issues are being argued on appeal.

Finally, Dr. Chamberlain claims that he is confused as to what issues are being argued
on appeal. Specifically, Dr. Chamberlain maintains that he is confused as to whether Munson
is really meaning to appeal the trial court's "choice of sanction," or just the confidentiality
ruling itself. As with the alleged confusion regarding which ruling is on appeal, Dr.
Chamberlain argues that this confusion should serve as the basis for granting him a more
favorable standard of review.
As a threshold matter, the notion that Munson's response to the cross-examination
argument is somehow directed at the trial court's "choice of sanction" is simply incorrect.
Munson has not argued at any point in this process that a trial court must choose "sanction
A" over "sanction B" in a particular circumstance. By definition, the term "sanction" refers
to "a penalty or coercive measure that results from failure to comply with a law, rule, or
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order." Black's Law Dictionary, Sanction (8th ed. 2004). For example, the trial court below
"sanctioned" Munson by disqualifying her expert. By contrast, the cross-examination tools
discussed on pages 20-26 of the Opening Brief and again above (such as sealing the
courtroom or conducting an in camera review of the testimony) would not have punished any
party at all, but would instead have simply facilitated the cross-examination that Dr.
Chamberlain allegedly wants. As such, describing this response as advancing a "choice of
sanction" argument makes little sense insofar as there is nothing sanctionable about any of
these options.
Regardless, there are two basic problems with Dr. Chamberlain's argument that this
response should provide him with a more favorable standard of review. First, Munson was
quite clear in her brief regarding what was and was not at issue. Specifically, Munson
repeatedly and unequivocally stated that the issue on appeal was whether the trial court was
correct in concluding that the confidentiality requirement of Utah Code Annotated § 78-1412(l)(d) was violated in this case. See, e.g., Munson's Opening Br. at p.l ("That mistrial
ruling was in turn based on the trial court's erroneous interpretation of Utah Code Annotated
§ 78-14-12(l)(d)"); p.8 ("The trial court erred when it concluded that the confidentiality
requirement set forth in Utah Code Annotated § 78-14-12(l)(d) (2005) was violated in this
case"); p.8 n.4; p. 12 ("The trial court's threshold conclusion that there was a breach of
confidentiality in this case was incorrect."); p.26 ("The resolution of this appeal hinges upon
the question of what the Legislature intended when it designated the prelitigation process as
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'confidential.'5'). As the appellant, it is Munson's prerogative to determine what issues she
wishes to raise and argue, not Dr. Chamberlain's. Regardless of what this Court does or does
not do with the choice of sanction issue raised by Dr. Chamberlain, Munson as the appellant
is entitled to first receive a ruling on the question that she actually raised, and that ruling
should be governed by its own appropriate legal standard.
Second, to the extent that resolution of this appeal requires review of the trial court's
discretionary rulings, Utah law plainly holds that it is an abuse of discretion for a trial court
to base a discretionary ruling on a misinterpretation of law. See Munson's Opening Br. at
p.2 (citing cases for this proposition). Regardless of whether this Court focuses on the issues
raised in the Motion for a Mistrial, the Motion for Summary Judgment, or even the Motion
for Reconsideration, all of these rulings still turn on the correctness of the trial court's
threshold § 78-14-12 conclusion. If the trial court had properly interpreted that statute, the
trial would have proceeded as scheduled on February 25, 2004, and there would have been
no mistrial ruling, no reconsideration request, and no grant of summary judgment. Thus, it
is this single misinterpretation of law (which even Dr. Chamberlain admits should be
reviewed de novo, Dr. Chamberlain Br. at p.2) that set this whole chain of legal events in
motion, and all of the subsequent actions by the trial court, whether discretionary or not, were
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based upon that single ruling's validity. Munson has properly challenged that determination,
and it ought to be reviewed for correctness.6
CONCLUSION
The trial court's conclusion that a expert who is retained after a prelitigation panel has
concluded its work must then be shielded from all documents that were submitted to that
panel is flawed. This assertion is not mandated by either § 78-14-12 or Doe v. Maret and
it should now be overturned by this Court. Instead, this Court should conclude that retained
experts are allowed to view all information relating to a case, whether that information was
submitted to the prelitgation panel or not.
DATED this 2la- day of October, 2006.

i

R W N D. TENNEY, and
KENNETH PARKINSON, for:
HOWARD, LEWIS & PETERSEN
Attorneys for Appellant

6

In light of this, Dr. Chamberlain's repeated allegation that Munson has somehow
admitted that she has no expert is disingenuous. See, e.g.. Dr. Chamberlain's Br. at pp. 7-8,
15-16. As set forth throughout the arguments, motions, and briefing in this case, Munson has
maintained all along that Dr. Jacobs was a properly qualified expert and that he had a proper
basis for charging Dr. Chamberlain with having violated the standard of care. Dr. Jacobs was
only prevented from testifying at trial because of Dr. Chamberlain's assertion that Dr. Jacobs
had improperly viewed prelitigation materials-an assertion that has been directly challenged
at all stages of this proceeding. As such, there has never been a "concession" that Munson
had no expert or that summary judgment was appropriate.
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IN THE FOURTH JUDICIAL DISTRICT COURT IN AND FOR
2
UTAH COUNTY, STATE OF UTAH
3 REBEKAH MUNSON,
)
) Case No 010404581
4
Plaintiff,
)
vs
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BRUCE H CHAMBERLAIN, M D and)
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)
7
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Defendants

)

DEPOSITION OF ALEXANDER JACOBS, M D - November 18,2002

10
PURSUANT TO NOTICE, the deposition of ALEXANDER
11 JACOBS, M D was taken on behalf of the Defendants at
1200 17th Street, Suite 1900, Denver, Colorado 80202, on
12 November 18,2002, at 2 30 p m , before Marchelle Hartwig,
Certified Shorthand Reporter and Notary Public within
13 Colorado

14

APPEARANCES

15 For the Plaintiff
16
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KENNETH PARKINSON, ESQ
Howard, Lewis & Petersen
120 East 300 North
Provo, Utah 84603

17
For the Defendants
TAWNIJ SHERMAN, ESQ
Snell&Wilmer
15 West South Temple, Suite 1200
19
Gateway Tower West
Salt Lake City, Utah 84101
18

20
21
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WHEREUPON, the following proceedings were taken
pursuant to the Utah Rules of Civil Procedure.
* * * * *
ALEXANDER JACOBS, M.D.,
having been first duly sworn to state the whole truth,
testified as follows:
EXAMINATION
BY MS. SHERMAN:
Q. This deposition is being taken pursuant to the Utah
Rules of Civil Procedure. Could you please state your full
name and spell it for the record.
A. Alexander Jacobs, J-a-c-o-b-s, A-1-e-x-a-n-d-e-r.
Q. My name is Tawni Sherman. I represent Dr. Bruce
Chamberlain and the Central Utah Medical Center. This
deposition is a chance for me to ask you a few questions
about your opinion on this case. Til be asking you about
your background and your expert opinion on some of the
medical issues raised in this case. Have you been deposed
before?
A. Yes.
Q. How many times, ballpark if that's —
A. Ten times.
Q. Were those all in medical malpractice cases?
A. No.
Q. What other types of cases have you participated in?
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A. Workman's compensation, personal injury. This may
be the second time in my life I think I'm being deposed in a
medical malpractice case.
Q. So you are familiar with the sort of ground rules
for a deposition?
A. I think so. I am sure if I err, you will reguide me
just like the guidance systems on the car.
Q. I will certainly try to. But if I do ask a question
that you don't understand for whatever reason, just let me
know and I'll be happy to rephrase it.
A. That's acceptable.
Q. Also, any time you need to take a break, we are
happy to stop. Just let us know.
A. Thank you.
Q. Are you taking any medications today?
A. No.
Q. We ask because sometimes they can affect a
deponent's ability to understand and answer questions.
A. I thought perhaps you were suggesting I needed some.
Q. Having known you for only two minutes, I wouldn't do
that. Could you please tell me your address.
A. 3300 East 17th Avenue. Denver, Colorado. The zip
code is 80206.
Q. I have seen your CV, but I'll just go briefly over
some of the significant events in your history. Where did

Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

1 (Pages 1 to 4)

Page 7

Page 5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

you graduate from college, undergrad?
A. Yeshiva University, New York.
Q. What was your major?
A. It was kind of a mixed major. Arts and sciences.
The science major was biology and the arts was English lit or
something.
Q. Where did you go to med school?
A. University of Colorado Medical Center.
Q. When did you graduate?
A. In 1972.
Q. Did you have any awards or honors?
A. I did.
Q. What were those?
A. Gosh, I really don't even remember. A few awards
that are titled by the name of the donor and the person who
sponsored the awards, but -- you know, I think everybody in
medical school gets some sort of an honor award when they
graduate. I graduated with honors, if that makes a
difference. There were some awards for showing aptitude and
some for showing up every morning and some for not being sick
too often, that kind of stuff.
Q. Where did you do your internship?
A. At the University of Colorado Medical Center
Affiliated Hospitals.
Q. Any specialty?
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A. No.
Q. Have you ever had any malpractice claims against
you?
A. No. Thank God.
Q. You are a lucky man.
A. I am, and I thank God every day for it.
Q. Are you current on your continuing medical
educations?
A. Yes, I am.
Q. Do you have any CMEs or other training that applies
specifically to the opinions you will be rendering in this
case?
A. Well, as they relate to internal medicine, I get at
least 50 hours of continuing medical education per year.
Because I also teach at the university and have students,
there are additional hours of continuing medical education,
but that's more of the teaching format. It's all related to
internal medicine. I guess I'm not sure how it would relate
to the testimony I give you, but...
Q. But in a general way —
A. In a general way it's related to the treatment,
diagnosis, and taking care of patients.
Q. Please walk me briefly through your employment from
the time you graduated from med school until the present.
A. Well, from the time I graduated medical school, then
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A. Internal medicine.
Q. How about your residency?
A. Same place, same specialty.
Q. For how many years did you do the residency?
A. Well, the combined internship and residency was
three years.
Q. You are board certified in internal medicine?
A. Yes.
Q. In any other fields or areas of practice?
A. I am also certified as a medical director by the
American Medical Directors Association, and I'm also
certified as a level 2 rater for the Department of Labor,
Colorado Division of Workman's Compensation.
Q. The medical director certification, is that for your
work with nursing homes, medical centers, that sort of thing?
A. And hospice and home health and hospitals as well.
Q. You are licensed to practice medicine in Colorado, I
take it?
A. Yes.
Q. In any other states?
A. No.
Q. Have you ever had any disciplinary actions taken
against you?
A. Only by my wife.
Q. Any suspensions of your license?
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I did my internship and residency at the University of
Affiliated Hospitals. Then in 1975,1 graduated, finished.
I become board eligible, shortly thereafter board certified.
Then I started practicing in the location I mentioned before,
so I've actually been there for about 27 years.
Q. Have you ever published any articles or books?
A. I have.
Q. On what subjects?
A. Leukemia, sexually transmitted diseases. Those are
the only two that got kind of formally published and accepted
in what they call reviewed literature. I've had a number of
small things like in the Rocky Mountain Medical Journal and
things that I published in the university's letter that goes
out to students.
Q. You mentioned that you teach?
A. Yes.
Q. What subjects do you teach?
A. Internal medicine, clinical diagnosis, treatment,
and primary care, primary patient follow-up.
Q. How long have you done that?
A. Since I graduated from my residency.
Q. Have you ever served as an expert witness?
A. I think so. The definition of an expert ~ 1 think
your definition may differ from mine, but I think I
understand what you mean.
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Q. What is your —
A. Not just as - well, I don't know if I'm much of an
expert, but when 1 testify regarding a case that isn't just
my firsthand knowledge of taking care of a patient, it's
considered expert testimony.
Q. Right.
A. So, yes, I have.
Q. On how many occasions?
A. In my entire career, you mean?
Q. Yes.
A. That includes depositions and hearings?
Q. Yes.
A. Maybe 20 times.
Q. Do you generally testify for the plaintiff or the
defense? Can you characterize it that way or is it a mixed
bag?
A. It's a mixed bag.
Q. Do you consider yourself a part-time expert, an
occasional expert in terms of your service related to the
legal issues?
A. Well, if I'm classified as an expert, I guess I'm
always an expert. You mean, in terms of when I testify?
Q. In terms of the composition of your practice, I
guess. Some physicians spend almost full time working in
medicolegal consulting, some do it once a year, once every
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second case?
A. Yes.
Q. Were both of those cases in Colorado?
A. Yes.
Q. Briefly, what were the subjects involved in those
other two medical malpractice cases?
A. One of them was a patient who had a leg amputated
after developing a clot in her artery. The other case was a
patient who received two drugs that interact with one anotheii
and she developed a fatal heart irregularity that caused her
to die.
Q. Whafs your normal rate for expert testimony?
A. $500 an hour.
Q. Does that rate differ for consulting with the
attorney rather than testifying?
A. Yes.
Q. What's that rate?
A. I think $250 an hour.
Q. Who first contacted you to serve as an expert in
this case?
A. Dr. Kane, K-a-n-e.
Q. Do you recall Dr. Kane's first name?
A. I can find out by calling my office. I've only
talked to him twice and so I don't remember his first name.
But this is the first I heard of the case when he called me a
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couple of years.
A. The portion of my practice that's comprised of
medicolegal work is maybe 15 percent. It may be lower if I
exclude like workman's compensation rating, which I do for
the state.
Q. You mentioned that this is the second medical
malpractice case that you have been involved with?
A. That I can think of, yeah.
Q. Who were the lawyers involved in the other medical
malpractice case you were involved with? Are they Colorado
attorneys?
A. Yes. Cates & Company or Cates, et al. Cates &
Milzer, maybe is the name. One of them is also a physician
and an attorney. That was the other most recent case that I
testified in.
Q. In that case, did you testify at a deposition or in
court or both?
A. That was - actually, 1 just thought of another
case. So one of them was just a deposition and the case was
settled during the deposition, so that never even finished.
The other one is actually in court. The only reason 1
remembered it is because it was the same attorney.
MR. PARKINSON: If you would like to settle the case
during this deposition, feel free.
Q. (BY MS. SHERMAN) So you testified in court on the
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number of months ago.
Q. Did you know him previously?
A. No.
Q. Who is Dr. Kane?
A. I think he has some company that tries to find
people who are versatile in a given field so that when
somebody is looking for a physician to review a case, he kind
of hooks the two up together for a fee.
Q. Before you were contacted to serve as an expert in
this case, did you know the plaintiff, Rebekah Munson?
A. No.
Q. Did you know Mr. Parkinson or anyone in his law
firm?
A. No.
Q. When did Dr. Kane first contact you?
A . I don't remember the exact date.
Q. Month and a year would be fine.
A. Yes. A number of months ago.
Q. Was it in calendar year 2002?
A. Yes.
Q. Spring; do you remember?
A. I think in June or maybe May.
Q. You said Dr. Kane called you?
A. Yes.
Q. How long did that first discussion with Dr. Kane
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last?
A. Five minutes.
Q. What did he tell you or ask you in that
conversation?
A. He asked me if I see patients with polymyositis and
if I treat polymyositis and would I be willing to review a
case from out of town, and I think that was the gist of it.
He may have even told me a little bit about the case, but it
was just in very vague terms.
Q. Have you seen patients with polymyositis?
A. Yes.
Q. Do you have an engagement letter or other written
agreement either with Dr. Kane or with Mr. Parkinson?
A. None with Dr. Kane. And 1 certainly don't have a
letter, but we have an agreement that he has paid me for
reviewing the records. He took me out to lunch today. We
had an agreement that we would drive up here together. We
don't have any kind of a formal contract. I don't work for
Mr. Parkinson or his company.
Q. How much have you been paid so far to review records
in this case?
A. I don't know for sure. Several hundred dollars,
maybe six or eight. I am really not sure. My office manager
could tell you.
Q. When was your first contact with Mr. Parkinson?
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A. 1 think my conclusion in the letter to them after
reviewing those additional records was that -- and I quote,
"In general these notes do not add much to the main question
of corticosteroid usage for prolonged periods and its
intended complications in a patient with at best questionable
indications." So there wasn't really any ~ 1 didn't change
my mind or anything. It basically reiterated what I had
already concluded. You know, that letter was in June, so my
date as to when I started with all this must have been a
little bit before then, maybe even May or April.
Q. Thank you. How many hours have you spent on this
case so far?
A. Well, I've spent about three or four hours reviewing
the data and then another two or three hours — actually, a
little over three hours yesterday re-reviewing the data, and
I don't know, maybe another hour or two. It's hard to guess.
Maybe 10 or 12 hours total. Some things just take longer.
Trying to decipher handwritten notes is very time-consuming,
but reading several pages of typewritten notes is very quick.
I don't remember exactly, but that's something I can get for
you because my office will bill for the time I spent.
Q. So you did keep records of your time?
A. Records of how much time was kept and how much was
billed and at what rate.
Q. Your office manager has those?
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A. In person or by mail or »
Q. Any contact after Dr. Kane connected the two of you.
A. I think a couple of weeks after Dr. Kane got in
touch with me, I got a letter telling me, Thank you for
agreeing to review the case; and then shortly after that it
was followed by some records for me to review. I think there
may have been something in the letter about the fee
structure, which Dr. Kane also reiterated, I think. Not just
reiterated, but actually suggested, because I really wasn't
sure what was in the ballpark and what wasn't. And until
today, I don't think we have spoken or met. We may have had
additional communications. For example, there was a second
mailing, but, then again, I think it was handled mostly by
paralegals and so on and so forth, but always over the
signature of Mr. Parkinson.
Q. What was in that second mailing from Mr. Parkinson?
A. The second mailing was actually from a Heather
Finch, which, I guess, is one of the paralegals there. I'm
not sure. They had forwarded some additional records that
covered office visits from June 18, 2002 dating backwards in
time to September of 1999. And because these records weren't
included in the original mailing, the question was. Did this
in any way alter or change my opinion or what I thought of
the additional records?
Q. Did those records affect your opinion of the case?
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A. Yes.
Q. Have you spent any time consulting with anyone
besides people from Mr. Parkinson's office? Any other
physicians? Any nurses?
A. No.
Q. Shared any opinions with your colleagues?
A. No.
Q. How much additional time do you contemplate spending
on this case?
A. None, I hope. After I'm done, the two sides will
come out, shake hands and say, Good-bye, everything is fine.
Q. What documents have you reviewed in preparation for
your testimony today?
A. You mean besides the records that were sent to me?
Q. So you have reviewed the medical records?
A. Yes.
Q. Anything else?
A. I don't think so.
Q. In formulating or preparing your opinion, did you
review any treatises or medical texts or articles, things of
that nature?
A. Not so much in preparation for the deposition, but
when first getting the case. 1 think I went over the
Rheumatology Primer. It's kind of an annual printout of
what's new in rheumatology and what's new in collagen
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vascular diseases. I remember going over it briefly, and I
remember last night saying, Gee, I wonder where the copies
are I made of that? I couldn't locate them. I did look over
to kind of refresh my memory, and to look to see if there is
something new and exciting.
Q. Is the Rheumatology Primer a newsletter or a
journal?
A. It's a book. It's kind of a paperback large book
that's printed by the American Rheumatologic Association.
Q. Is that revised yearly?
A. I think yearly, perhaps every couple of years. In
some diseases there isn't much change made from year to year,
so it's pretty much like the previous book. And in some
diseases not only are there changes, but they are only
diseases to contemplate, so obviously the changes are quite
profound.
Q. Did you find anything in the Rheumatology Primer
that applied to the facts of this case?
j
A. Not anything new. Pretty much the old things that
have been true for a number of years when it comes to
diseases of the joints and muscles and of the immune reactive
nature.
Q. So did you review sections on polymyositis?
A. Yes.
Q. Anything else that you remember?
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MR. PARKINSON: Just for clarification on the
record, we did have a phone call.
MS. SHERMAN: You did have a phone call?
MR. PARKINSON: Yes.
Q. (BY MS. SHERMAN) Do you have plans to discuss this
case or consult with anyone else?
A. No.
Q. To prepare for your deposition, I know you've
touched on this briefly, but you reviewed the medical
records, you had lunch with Mr. Parkinson today. Is there
anything else that you did to prepare?
A. No, nothing specific.
Q. Is that your file in this case?
A. Yes, it is.
Q. What documents or materials do you have in that
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A. Well, I have some of the communications. I have a
copy of a letter I sent on June 26 after reviewing the
additional records that were sent to me.
Q. That was a letter to Mr. Parkinson?
A. Yes. But it was actually addressed to Ms. Finch at
the Howard, Lewis & Petersen, P.C. law firm. What was I
telling you, what I have here?
Q. The contents of your file, yes.
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A. Sections on ankylosing spondylitis.
Q. Have you read any deposition transcripts taken in
this case?
A. Well, not really. I wasn't even aware of any until
today at lunch when I was kind of told that there had been a
deposition, and asked a few questions regarding the
deposition.
Q. Regarding the deposition of Ms. Munson or of
Dr. Chamberlain or both?
A. Of Dr. Chamberlain only.
Q. Have you reviewed any interrogatories or responses
to interrogatories?
A. No.
Q. Any of the other pleadings or legal papers filed in
this matter?
A. No.
Q. Have you ever had a discussion with Rebekah Munson?
A. No.
Q. Today was the first time you talked to
Mr. Parkinson?
A. Yes. Well, to the best of my knowledge. I don't
think we have talked before. As I said, we communicated by
mail. There may have been one discussion before or shortly
after 1 got the notes, but 1 am not sure of that. But he can
answer that question for us if his memory is better about it
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A. Notes of clinical visits from Dr. Call and
Dr. Chamberlain and Dr. Gremillion and Dr. Rosenthal and
Dr. Watkins, and even some communications from Dr. Jones.
Q. Anything else in the file?
A, When I originally reviewed the file, I took some
notes. I reviewed those as well.
Q. At one time, you had some of the articles from the
primer?
A. I had somefromthe primer, and also from textbook
of internal medicine regarding dealing with these two
diseases.
Q. Do you recall which textbook?
A. I think Harrison's.
Q. Do you consider Harrison1 s to be authoritative in
the field?
A. Yeah. Harrison's is pretty authoritative in all
internal medicine.
Q. How about the Rheumatology Primer, do you consider
that to be authoritative and reliable?
A. It's more specialized because it deals just with
rheumatologic diseases, but yes, it is.
Q. Now, I have received a report you prepared dated
June 5, 2002, or a report that you signed.
A. Perhaps that report is with copies of some of the
literature.
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Q. I'll give you a copy when we get to discussing that
in a little more detail. Did you prepare that report?
A. If you can show it to me, 1 will be able to answer
that question because I am not sure what we are referring to.
MS. SHERMAN: 1 will offer this as Exhibit 1.
(Deposition Exhibit 1 was marked.)
THE DEPONENT: Yes, 1 prepared and signed this.
Q. (BY MS. SHERMAN) So you recognize that report?
A. Yes.
Q. When did you finish that report?
A. June 17, 2002.
Q. Could it have been May 17?
A. Well, it's dated June 17.
Q. I'm sorry. I was looking at the front page.
A. I guess maybe I dictated it on June 5.
Q. Do you recall dictating this report?
A. Yeah, vaguely.
Q. Did you dictate that to your secretary or to someone
in Mr. Parkinson's office?
A. No, to my secretary. It's based actually on a
report that maybe ~ here it is. I do have it. It's based
upon a report that I prepared shortly after reviewing the
medical records, which is kind of a summary of the medical
records and some sort of a temporal representation of what I
read. It's dated March 4, 2002. Actually, that report helps
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through the report with you and ask you a few questions about
that in detail. What facts have you relied on to reach your
opinion? And when I say "your opinion," for purposes of the
deposition, we'll refer to the June 17 report.
A. Okay. Well, the data on which that opinion is based
is my medical education, my knowledge of medicine, my
knowledge and experience in treating patients with this
disease, and the records as they were submitted to me. and
review of all the physicians, their care, their notes, their
opinions, and their plans regarding this case.
Q. How many patients with polymyositis have you
treated?
A. Probably half a dozen in my entire career.
Q. Is there a difference between myositis and
polymyositis?
A. Well, myositis is kind of a nondescript term. It
just means muscle and formation. Polymyositis is a name of a
disease, a specific disease. So, yes, there is a difference.
I guess it's like headaches and migraine.
Q. What are the hallmarks of polymyositis?
A. The hallmarks of polymyositis is muscle weakness and
muscle pain, proximal more than distal, inflammation,
tenderness. In addition to pain, there is actually
tenderness to the muscles. There is a feeling of malaise and
fatigue, weakness. Generally there is clinical history of
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me answer a previous question because at that point I had
spent 4 1/2 hours reviewing the records.
Q. You have a copy of that report there in your file?
A. Yes.
Q. When we take a break, Til ask to take a look at
your file.
A. Okay.
Q. Did you prepare any drafts of your June 5 report?
A. Drafts of which report?
Q. The June 17 report.
A. Well, I think that this was the draft. This March 4
report, which was a summary of my record review and my
opinions kind of acted as a draft, and I see now that this is
kind of just formalizing this report.
Q. Okay. Were there any changes between the March and
the June reports?
A. No.
Q. Did anyone assist you in preparing your report?
A. No.
Q. Are you going to be rendering any opinion regarding
Central Utah Medical Center?
A. No.
Q. Now, I would like to get to your opinion in this
matter. First, I'll ask just some general background
questions about the bases of your opinion and then I'll go
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gradual progressive pain, difficulty in doing acts of daily
living such as getting up out of a chair or reaching high
items up on shelves, which again is testament to the proximal
distribution. But in severe cases, it reaches distally as
well. The features include not only those clinical aspects,
but they include elevation of the sedimentation rate,
C-reactive protein, elevation of creatinine phosphokinase,
which is a muscle enzyme, along with aldolase, which is
perhaps more specific.
Q. Elevated aldolase, then?
A. Yes. Other hallmarks include a specific
neuropathology that can be documented by electromyographic
testing, but the hallmark and possibly the gold standard is a
muscle biopsy that actually shows the perivascular and
perimyositis inflammation, the leukocytosis, the white blood
cell predomination and lymphocyte gathering around muscle
cells and various states of muscle destruction and muscle
rebuilding, muscle scarring and the inflammatory response.
Q. In the roughly six patients you have treated with
polymyositis, what has been your clinical course of those
patients, if you can generalize across the six?
A. Well, polymyositis can be divided into a number of
different diseases. The cases I'm talking about are patients
with fairly pure polymyositis, because polymyositis-like
diseases can be identified as a perineal plasty syndrome. In
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other words, an association with some kind of cancer. It can
be associated with other collagen vascular diseases like
lupus or Sjogren or scleroderma. It's also not an uncommon
feature to have polymyositis and dermatomyositis together
where there is a tremendous amount of skin involvement in
addition to the connective tissue of the muscles. So of the
pure polymyositis patients I have had, their clinical course
has been variable. Those that have mild symptoms and were
relatively younger did well and responded to
anti-inflammatory drugs.
Q. Such as? Like, just NS?
A. Nonsteroidals as well as steroids. Those who were
older — eventually, unfortunately, these patients convert to
patients who have an occult malignancy because it can precede
the obvious cancer by months or years. So actually you have
to look for an occult tumor even though you are treating a
patient whom you've diagnosed with polymyositis. Their
prognosis, obviously, is much worse.
Q. By "occult," is that hidden?
A. Right. So the answer to your question is, it's
really variable. It's really variable as to how well they
do. Those who have the pure diagnosis without other
associated factors and those who are relatively young, they
respond very quickly and very well to steroids.
Q. How many of your patients were this younger,
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mentioned you thought they were doing well.
A. One of them is a friend of a patient who is still
one of my patients, so she frequently sends regards when she
sees me. She is still doing well. She is the one that lives
in California.
Q. Do you know if she is still on steroid treatment?
A. She is not.
Q. Do you know if the other one is still on steroid
treatment?
A . I don't know anything about the other one.
Q. When you say these were lower doses of steroid
treatment over the long term, what kind of doses was it that
you had them on?
A. Once you've gotten a good response, you find the
lowest possible dose to keep them asymptomatic, and then
sometimes you switch to alternate-day steroids, and that
helps reduce the side effects. So if you have a patient,
let's say, who is doing well on 20 a day, you might go to
40 every other day. It's the same dose and you get pretty
much the same effect that's therapeutic, but you get
significantly lower side effects.
Q. Do you recall what doses you had those patients on?
Were they on a 20 milligram maintenance dose or 40 every
other day, or was it some other —
A. Something in that range. The most important thing
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mild-symptom profiles?
A. The two or three I can think of right offhand did
very well with short courses, converted pretty quickly to
alternate day therapy. Unfortunately, both moved away. One
to the West Coast and one somewhere in Florida. The last I
heard, they were still doing very well, and this is maybe ten
years after the diagnosis.
Q. Which steroid did you use to treat those two or
three other patients?
A. One prednisone and one prednisolone.
Q. When you described a "short course" of steroidal
therapy, what is a short course?
A. Well, a short course is one to four weeks. But what
I was saying is not that they were on a short course, but
they responded to a short course, so the response was pretty
quick and dramatic.
Q. So they responded well within roughly one to four
weeks. For how long did they continue to be on the steroid
therapy?
A. Years, but at lower doses and switched to alternate
days or courses. One for three years and one for four years
until she moved away.
Q. Were they both women?
A. Yes.
Q. Have you been in touch with either - I know you
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is to use clinical parameters.
Q. Such as?
A. Well, you basically constantly weigh the therapeutic
benefits versus the potential and the actual side effects.
So if the patient is doing very, very well and they have no
muscle aches, no pain, no redness, no irritation, they can do
all of their acts of daily living, you go ahead and cut the
dose. If they continue to do well, you wait the respectable
period of time — and I'm talking about weeks as opposed to
days or months — and you cut it again. Then if the patient
starts saying, I'm having muscle aches; my shoulders are
hurting now, they feel warm to the touch, they are stiff,
they are weak, I can't lift the baby anymore, you go back to
your previous therapeutic dose.
Sometimes you actually have to go a little bit
higher in order to achieve the effect and then come back to
the previous dose. So you keep them there a few extra months
and then try to taper again. But even if you can't taper,
you really achieve a lot of improvement by going to double
the dose but alternate day.
Q. Is that what I've heard described sometimes as
"empiric therapy"?
A. No. Empiric therapy means treatment without a
diagnosis. That's what empiric means. In other words, if I
get a patient who gets admitted to the hospital with sepsis,
|
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I know they are infected and they have a life-threatening
infection, I'll treat them with antibiotics empirically
without knowing what bug they have or even which antibiotics
are liable to work. But you try and shotgun-treat every
possible likely infection until you get back culture results
and then you trim the therapy so that you are giving them
just what they need, not a lot of accessory stuff. That's
where the side effects are.
So empiric treatment is something that we usually
reserve for life-threatening cases. It's not the standard
for medicine to treat everybody empirically. That's like
giving you nitroglycerin because you come in with a little
chest pain and it turns out to be a musculoskeletal strain.
Q. So you are saying you follow the clinical signs. Is
that as reported by the patient? Do you do any lab work?
A. Well, "clinical" means not only as reported by the
patient, but also based upon your examination. So the
clinical is the history and the exam. And then laboratory
data generally is used here to kind of- how shall I say
this - kind of fortify your opinion. The problem with lab
work is that once a patient is on treatment, the lab work
becomes much less reliable.
Q. Because of the effects of whatever the treatment is?
A. Some of the medications will affect the lab work
more than they affect the patient. With steroids especially,
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led down the primrose path that ultimately will wind up with
a dead patient. I don't know if I made that clear.")
Q. (BY MS. SHERMAN) If you will take a look at
,
Exhibit 1. You indicate in the paragraph marked 1 that
prednisone was given as early as 1998.
A. Yes.
Q. Who is it that prescribed the prednisone in 1998?
A. Well, I don't remember right offhand.
|
Q. I was wondering, because as far as I know,
Dr. Chamberlain didn't prescribe prednisone until 1999.
A. You know, of all these doctors' reports that I
reviewed, in some of them there may have been some
contradiction. I know that she received prednisone early in
1999 as a consequence, I think, of an operative procedure
that may have been at the end of 1998. Maybe that's what I
meant.
I know that there was an initial treatment with
I
prednisone at extremely low doses that was felt to be very '
effective in relieving her symptoms. This somehow was later
misinterpreted as a reason to continue treating with
prednisone at much higher doses.
I
It was, I think in September of 1998, that the
patient had some fascial surgery, and sometime after that
surgery, she developed severe leg pain, she couldn't stand,
so she went back to the hospital and she was found to have a
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you can actually get a reverse effect. Steroids can
sometimes aggravate a myopathy, particularly if they don't
have polymyositis. You have to be careful.
Q. Is it your opinion that that happened in
Ms. Munson's case; the steroids aggravated a myopathy?
A. I think it's possible. It occurred to me. That's
why we kind of just naturally look for a good initial
response with a therapeutic dose before we say, Okay. And
you look for a very confirmed diagnosis because otherwise
steroids will make you much worse instead of much better.
Then if you attribute it to the disease instead of your
medication, you are kind of led down the primrose path that
ultimately will wind up with a dead patient. I don't know if
I made that clear.
Q. Yes, you did.
MS. SHERMAN: Could you read back his answer,
though, because three or four questions sprang to mind at the
same time.
(The last answer was read back as follows: "I think
it's possible. It occurred to me. That's why we kind of
just naturally look for a good initial response with a
therapeutic dose before we say, Okay. And you look for a
very confirmed diagnosis because otherwise steroids will make]
you much worse instead of much better. Then if you attribute
it to the disease instead of your medication, you are kind of
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condition called rhabdomyolysis. And at least in one of the
reports here ~ although 1 never found primary evidence for
that in the record, that is, a report from that time -- said
that she was treated with prednisone at that time for an
elevated sed rate and a high CPK, that's a creatinine
phosphokinase muscle enzyme, and that she responded and got
well. So it could have been an error, but one of the
consultants here dated it to 1998.
Q. Thank you. Now, you indicated that the short course
of treatment in early 1999 seemed to help, and I think you
said it was misinterpreted as providing grounds for her going
back on the steroids.
A. Because later on I saw that kind of use as
justification for the diagnosis and for treatment of
steroids, but in truth, she was on 10 or 20 milligrams,
extremely low doses.
Q. Initially?
A. Right. And was actually given some IV fluids during
that course of rhabdomyolysis, which really is what made her
better.
Q. The IV fluids?
A. Right, which is the real ideal treatment for rhabdo.
And the physician who followed her then may have even
suggested that she had a myositis. Again, that's a more
general term. Because myositis could be a phenomenon
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attributable to rhabdomyolysis, which is kind of a pressure
destruction of muscle.
Q. What causes the rhabdomyolysis?
A. Pressure. If you put enough pressure on a muscle
for long enough it starts to disintegrate.
Q. Would that be the pressure of lying on the operating
table during the fascial revision or more internal pressure
from the inflammation?
A. No. It's usually external pressure. In fact, the
most common cause of rhabdomyolysis in my practice, and
probably in internal medicine, are elderly people who fall
and can't get up and someone doesn't come to check on them
for hours or days. In many cases it's fatal. They develop a
rip-roaring rhabdomyolysis with CPKs in the thousands. If
the kidney can't clear the myoglobin, the muscle proteins
that are released in these dead muscles, they go into renal
J
shutdown and they can die.
Generally healthy people, a, could tolerate that
load of myoglobin, but b, are rarely found to be incapable of |
getting up after falling even with a broken leg or something, I
and even without attention or help from other people. They
can usually drag themselves to get to a phone or something.
So rhabdomyolysis is generally caused by external pressure
that destroys muscle cells.
Q. The preferred treatment for that is hydration?
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its own, and that's why you have to taper. That's why you
can't stop prednisone suddenly. Because if you stop suddenly
and your own adrenal gland hasn't awakened to start producing
its baseline amount, you will end up in an Addisonian crisis.
You will have no steroids at all. That in itself can be
fatal.
i
Q. Did you say "Addisonian"?
A. Right. So the point is that the initiation of
exogenous steroid treatment generally suppresses the adrenal
gland from making its own prednisone equivalent. So that's !
why 10 milligrams a day, or 20, it's not really enough for a
patient who has polymyositis. In fact, if you didn't get a
good response and had good evidence for a diagnosis, which
was missing here all along - but if you had good evidence
for a diagnosis and they didn't respond to 10 milligrams or
20, you would be obligated to go to 40 or 60 or 80 a day.
But as soon as you get no response to that after a
couple of weeks or when the side effects outweigh the
benefits, you've got to rethink things and say, Hey, this
isn't polymyositis. This is something else. Let's go back
to the drawing board.
Q. But in this case where they started at the low dose
and seemed to have a good response, when her symptoms
worsened, why was it improper, then, to try a little higher
dose?
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A. Well, you have to stop the offending agent and get
them off their muscle and help their body. It's kind of
really supportive care. You can't do anything about the
muscles that have already been damaged. So mostly you
support them. If they are having renal shutdown, you have to
dialyze them. You give them lots of fluids to wash out the
myoglobin. If they develop hypotension, you support them
with fluids. If they develop cardiac dysrhythmias, you have
to give them something to regulate their heart rate.
Q. You indicated earlier when you were discussing the
patients that you had treated with polymyositis that if they
feel better you taper the steroids, and if they come in and
their symptoms have worsened, you might bump it up a little.
A. Right.
Q. I am curious how that plays in with your statement
that Rebekah Munson's initial good response to the steroid
treatment - that coming back and treating it with steroids
was inappropriate?
A. Well, my feeling is based upon the fact that that
initial treatment with steroids was too low a dose to do
anything.
Q. 10 to 20 milligrams a day?
A. Right. 10 milligrams a day-you know, your own
body makes the equivalent of about 5 or 7 milligrams a day.
The minute you get that much or more, your body stops making
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A. Because the fact that she responded to such a low
dose is probably not an indication of treating the proper
disease. That's just the first factor. The second factor is
that prednisone even at low doses can mask symptoms.
Prednisone is a medication that's fraught with so many
complications that if you know anything as a physician, you
have to know that you better be certain about what you are
treating and why you are treating it. In fact, we are
obligated now to give a patient a disclaimer or an
informed-consent form that lists like 14 or 16 different
horrible things that can happen if they are taking prednisone
to make sure that they understand they are willing to take
that risk.
This is when you know about the diagnosis. When you
don't know about it, you are much less likely to try this.
That's why nowadays since we live in such a litigious
society, a lot of internal medicine specialists make the
diagnosis and refer the patient to a rheumatologist.
MS. SHERMAN: Could you read the first few sentences
of his response.
THE DEPONENT: I think the first response was that
when the dose is too low, you can't depend upon it telling
you something. The second part was that it may mask things
and so it gives you a false sense of security, and the third
thing is that because the complications are so severe, you
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have to be very certain about your diagnosis when you start
pushing big doses.
Q. (BY MS. SHERMAN) Thank you. So when you said
initially when the dose is so low you can't rely on it
telling you something, to what then do you attribute her
initial favorable response?
A. Time. Things like muscle aches get better, rhabdo
improves. You get rid of fluids, you get rid of the
myoglobin, the muscle heals and she is back to normal.
Q. So do you agree with the initial assessment of
rhabdomyolysis?
A. Yes.
Q. Is it in any way significant to your opinion of

Dr. Chamberlain's care that he had referred Ms. Munson to a
rheumatologist in March of '99, and that she didn't want to
follow up on that because of concerns about money and driving
the distance from Provo to Salt Lake?
A. What's the question?
Q. Is it significant to your opinion — you mentioned
that one thing that would be important would be to refer the
patient to a rheumatologist. And, in fact, Dr. Chamberlain
did refer Ms. Munson to a rheumatologist in March.
A. Well, yes, it is significant to my opinion.
Q. In what way?
A. A, the fact that a patient refused to see a
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appropriate. I'm not sure about the diagnosis, that's why I
want you to see a rheumatologist.
In fact, when she saw this rheumatologist the first
time, as I recall, his opinion was that she did not have
polymyositis. She didn't meet the criteria. Now, the fact
that she doesn't want to go back and confirm that opinion is
something that Dr. Chamberlain has to deal with. But one of
the ways to deal with it is, Look, you don't want to go back
and see him, you don't want to get confirmation of this
disease, here is my feeling. You are willing to come and see
me, perhaps I'll even see you free of charge ~ I mean, I
don't know what rates he had — but I'm going to start you on
medication that has some pretty significant side effects. If
I'm right, you are going to feel great. If I'm wrong, it may
not make you feel better, but you nevertheless may suffer
some consequences. Do you agree on embarking on this kind of
a course? And if she says, Yes, 1 do, let's go ahead and try
it, that's the third option. That's a thing you can do.
Now, again, in this day and age, that's not something that
very many doctors either have the time, the willingness or
the patient cooperation to be able to do it.
Q. (BY MS. SHERMAN) Is it your understanding that
Dr. Chamberlain did not have any such conversation with Ms.
Munson?
A. I reviewed his notes and his records and I didn't

Page 38

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

specialist is not reason to go ahead and start treating her
as though she has that disease without the benefit of special
consultation. B, if money is an issue and she can't afford
either the travel or the care she is going to get, there are
resources in every state and in every city to help take care
of patients like this. There is a state hospital, there is a
city hospital, and because this is an interesting case, the
university will take teaching patients at no charge; they
will allow the students to learn something from it.
In this day and age it's not an excuse to give the
patient the wrong medication and cause side effects because
they can't afford to see a consultant or don't have time to
drive to see a consultant.
Q. Did you have a "C" for that list? I think you had
initially indicated you had three points on that.
A. What was my first point?
(The last answer was read back as follows: "A, the
fact that a patient refused to see a specialist is not reason
to go ahead and start treating her as though she has that
disease without the benefit of special consultation.")
THE DEPONENT: And thirdly, I guess an acceptable
approach is to say, Look, you don't want to see this
consultant I selected for you, you can't afford to see a
different consultant, let's sit down and discuss what we can
do. I can start putting you on medications that I think are

Page 4 0

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

see any such thing. In fact, even the most basic of informed
consents for taking prednisone, I didn't see any such form in
the records.
Q. You mentioned that some internal medicine physicians
are giving detailed written consent forms for the use of
prednisone or other steroids.
A. Yes.
Q. In your opinion, is that the standard of care now
for a physician to use a form such as that?
A. I know that in this state the malpractice carriers
are saying it is. They have gone so far as to design such an
informed consent. I know that rheumatologists use it and I
know that most internists that I deal with and have gone to
school with and have trained with do something like that. If
they don't actually have them sign the form, which I do. they
at least put in their notes, I have gone over this form with
the patient and he or she agrees, and then maybe even put a
copy of such a form in the chart so that there is some record
later on that this was done because we are operating in an
arena where if it's not recorded, it wasn't done. That may
or may not be true, but that's the standard on which we are
judged.
Q. So in Colorado, it's approaching a standard of care
to use that form?
A. I think so. I think if you asked a rheumatologist,
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Do you always do that? They'd say, Yes. If you ask an
internist, Do you always caution a patient about steroids?
They would say, Yes. You would say, Prove it; show me in
your chart where you said you told the patient. At least get
I
the patient to agree you told the patient.
Q. Do you know if using such a form is the standard of
care in Utah?
A. I do not know. I know, for example, however, that
the standard in Utah is to caution every patient about every
drug you give them and its potential side effects because
that's the standard in the whole country.
Q. You mentioned towards the end of paragraph 1 that
Ms. Munson, when she saw Dr. Gremillion, he tapered her off'
of steroids and replaced it with methotrexate, a
nonsteroidal.
A. Yes.
Q. Is the methotrexate a good prescription in your
opinion?
A. It all depends. I think Dr. Gremillion, if I am not
mistaken, he was operating under the diagnosis of an
ankylosing spondylitis. Methotrexate, actually, when used
judiciously as a cytotoxic drug, is in many ways safer than
prednisone.
Now, when you use it at chemotherapy levels, that's
not true. Methotrexate has a number of different
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opinion that the polymyositis - strike that. Let me just
skip over that paragraph. I already covered some of this.
In paragraph 6, you state that Dr. Gremillion diagnosed
Ms. Munson with spondylitis. Is that the same as the
ankylosing spondylitis that you mentioned?
I

A. Yes.
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indications. When it's used in rheumatologic diseases, which
both polymyositis and ankylosing spondylitis can be placed,
methotrexate is sometimes safer than even nonsteroidal. Most
rheumatoid arthritis patients have just done beautifully with
the cytotoxic drugs. I hate the use of the word "cytotoxic."
That in itself is scary for patients. But basically what you
are doing is you are inhibiting the cells in the blood that
are responsible for the inflammation from doing their job.
Now, there are certain precautions you have to take.
You have to make sure that the platelets don't go too low,
that the white cells don't go too low, that their lymphocytes
don't go too low, that the hematocrit stays normal. It's not
always so simple. But if you can manage that and give them
methotrexate, they have phenomenal responses, and you can
actually have reversal of certain, you know, deformities
caused by the rheumatologic disease.
Q. We have been going about an hour. Do you want to
take a quick break?
A. I think that's a good idea.
(Recess taken.)
Q. (BY MS. SHERMAN) Returning to your expert witness
report dated June 5 or June 17, in paragraph 2 you mention
that the muscle biopsy on Rebekah Munson was negative,
showing no evidence of myositis. The EMG is completely
negative. No evidence of myopathy or neuropathy. Is it your

I

Q. Is it your opinion that that is what Ms. Munson
actually had, or can you tell?
A. I can't tell, you know. But Dr. Gremillion makes a
very cogent case for it. Even so, she is an exception to the
rule. She is what we call seronegative ankylosing
spondylitis. But a certain percentage of the population, as
high as 10 percent, are seronegative.
Q. What does that mean?
A. Ankylosing spondylitis is a disease that has a very
high association with a genetic marker. One of the genetic
markers we use in blood typing is an HLA B-27 categorization.
And patients with ankylosing spondylitis, the vast majority
of them, have this genetic predisposition. For a long time
it was felt it was a genetic disease because of it, although
we have now found that there are some markers without the
disease, so it's not a one-to-one relationship.
The theory is that you need this marker as a
predisposition and then something else, maybe a viral
infection or maybe — it takes more than just the marker.
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But the marker certainly makes you predisposed. She doesn't
have the marker. Not everyone does. But she has the very,
very strong correlative radiographic findings of closing of
the sacroiliac joints.
Q. That's the hallmark of ankylosing spondylitis?
A. There is one hallmark that's even more likely, more
predictive of the disease, but that happens must later in
life, so she may develop it years from now.
Q. What is that other element?
A. It's a fusion of the different vertebral bodies to
the point where the entire spinal column starts looking like
one gigantic long rod and you lose all the mobility in your
back because of it. That's only a small problem because you
don't use that joint. Only under pathological conditions is
there movement there. It's kind of a frozen joint. But when
the joint obliterates, it means that the joint is closing.
When the joint starts closing between the lower lumbar
vertebral bodies one by one by one, pretty soon you have
basically a ramrod spine and you can't turn and you can't
walk.
Q. That reminds me to sit up straighter.
A. Yes.
Q. Touching on your conclusions regarding the standard
of care, you say that the standard of care was breached by
Dr. Richard Chamberlain for the following reasons:
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Prednisone therapeutic trial should last a week, two weeks or
at the most three weeks. Now, I thought you had stated
earlier that in some cases it can go on for years. So could
you explain the parameters of those two statements.
A. Of course. Can 1 first just ask where you were
reading that?
Q. Yes. Page 2, although these pages aren't numbered.
A. What number?
Q. Number 1 midway through the page.
A. See, now here it's talking about a therapeutic
trial. A therapeutic trial means we are not sure about the
diagnosis and we have doubts, so we are going to give you a
medicine that isn't so much the conclusive treatment for what
you have, but a trial. In other words, we are going to try
you on it and see if you get better. If you get better,
great, then we'll continue to monitor for possible other
diagnoses and, of course, for side effects, which you always
do, but at least we are going to forge on with the treatment
since it's helping.
But if you don't improve, and certainly if you
develop side effects from the treatment, we are going to back
off and go back to the drawing board.
Q. So do you consider in this case the therapeutic
trial was the initial prescription of steroids in January, or
are you looking at when she resumed taking the steroids?
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treatment.
A. Right.
Q. What should Dr. Chamberlain have done?
A. He should have said, Look, the only reason we put
you on these drugs is because you refused to go back to the
specialist. We still don't have a firm diagnosis. All the
criteria, the EMG is negative, the muscle biopsy is negative,
the clinical improvement we expected hasn't occurred, and you
are suffering all these side effects. Let's get you off the
prednisone. Once you are off the prednisone we will recheck.
We will do another diagnostic workup, and let's find out what
you are getting. If I fail to be able to come up with a good
diagnostic working hypothesis, please let me refer you to a
rheumatologist.
You know, ultimately that's what she did anyway, but
she could have been saved a whole year's worth of problems
and an extra 100 pounds of weight and this cushingoid
appearance and high blood sugars and gallbladder disease and
continuous yeast vaginitis. I mean, all of these things are
a consequence of her steroids, and I am sure that she's aware
of that.
Q. So is it your understanding that she gained
100 pounds during her treatment with steroids?
A. Well, during that year she gained nearly 100 pounds.
She went from the 250 range to the 350 range or 330 range. I
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A. When she resumed taking the steroids. As I
mentioned before in the deposition, I don't think that
10 milligrams of prednisone or even 20 is really much of a
therapeutic trial. It's certainly not a diagnostic trial.
Q. Because it was a low dose?
A. It's too low a dose. You know, if I said, Well,
take this migraine drug, but take 100th of the normal dose
and you get better, is it because of that dose? You probably
just got better without it. It's not much of a therapeutic
or a diagnostic trial when you don't give an adequate dose.
Q. So other than saying that that January course of
steroids was lower than you would expect would show results,
do you have any criticism of his prescribing steroids as he
did in January?
A. Yes.
Q. What is that criticism or criticisms?
A. There is no evidence in the record that she was
given any kind of an informed consent. There is no record —
there is no evidence in the record that she was cautioned
about the potential harmful side effects. There is no
evidence in the record that she was told that this diagnosis
is questionable. I take issue with even giving 10 to
20 milligrams under those circumstances.
Q. You state that if there is no improvement, one must
challenge and question the diagnosis and certainly the

Page 4 8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

have it in those records that you currently have that are
being photocopied. She gained a tremendous amount of weight.
Q. Do you know if she had any prior history of having
vaginitis, the yeast infections?
A. Almost everyone has a history of yeast vaginitis at
one point or another, but she apparently developed such
severe problems that Dr. Chamberlain sent her to an OB/GYN
consultant, and apparently that she could afford.
Q. Have you seen her medical records predating her
treatment with Dr. Chamberlain?
A. No, but his note I think implied that this was more
than just a simple vaginitis and that it was continuous. In
fact, the consultant said, I'm considering maybe she has
diabetes to create this much of a problem because diabetics
are very prone to yeast vaginitis. The only thing he didn't
say is, Hey, it may be all these steroids, which he didn't
even mention as one of her medications, because that's the
other most common cause.
Q. Who didn't mention it, the consultant?
A. The consultant. He's looking for a reason why she
should have such a severe problem with vaginitis. And so he
said, I'll work her up for diabetes. I never saw whether or
not he did or what the results were. I know that there were
a number of blood sugars that were in the diabetic range and
a number of other blood sugars that were pretty normal. I
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wasn't able to correlate when the blood sugar was done with
what her course of steroids was, but that's, of course,
probably one of the most common causes of transient
diabetes ~ I think next to pregnancy — is prednisone
treatment.
Q. To some degree Dr. Chamberlain's treatment tracked
Ms. Munson's CPK and sed rate. What's your opinion of using
that as a marker to tailor this A. It's hard to because prednisone — it will
artificially lower the sedimentation rate even when the
degree of inflammation may not be lowered. It will mask it.
That's why it was implied before. Sometimes once you have a
patient on steroids, particularly at 40 milligrams,
60 milligrams, you are masking some of these markers.
Now, the nice thing is that usually the patient is
getting better clinically and the sed rate is going down. So
you have two pieces of evidence. But when those two aren't
concordant and when you have a sedimentation rate that's
rising and a patient is feeling better, watch out, because
you still could be barking up the wrong tree. When you have
a sedimentation rate that's coming down and the patient is
getting worse clinically, watch out because all you are doing
is artificially suppressing the sed rate and they are not
doing well.
The times when it really helps you is when they are
j
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muscles are susceptible to releasing enzymes. So CPK doesn't
help you, plus all the other enzymes that go up with
polymyositis were not up. She didn't have an elevated SGOT,
SGDT, LDH. I think there is only one time when an aldolase
was normal. Aldolase is a little bit more specific because
CPK is elevated from three different sources. It's not just
muscle.
Q. What are the other two?
A. Well, one of the places CPK is found in very high
concentrations is the brain. So the brain can raise CPK.
And in addition to the skeletomuscles, which we are dealing
with here, CPK is found in smooth muscle. Smooth muscle is
skeletomuscles, like involuntary muscles.
Q. Like intestines?
A. The intestines, the heart. In fact, when we
routinely assess a patient for a heart attack, we fractionate
the CPK. If the CPK is very high, you don't say, Yep, the
patient is having a heart attack, because it could have come
from his skeletomuscles, his biceps, his triceps, his quads
or his brain or from the heart.
So you want to — and there is a way to separate the
CPK to three fractions. Is it the heart fraction that's way
up? Ah, they are having a heart attack. This was the gold
standard enzyme before troponins were discovered. Troponins
are just recently discovered, which means as I get older,
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both getting better or when they are both getting worse. If
that's the case, what is the use of the sed rate,
particularly when you understand that a sedimentation rate,
although a very sensitive test, is an extremely nonspecific
test.
So her sed rate could have been up because of
ankylosing spondylitis. It could have been up because of the
dermabrasion. It could have been up because of
osteoarthritis of the knee. It could have been up because of
increasing vaginitis. It could have been up because she is
really heavy even before this all started.
So the sed rate is the last thing that you're really
going to rely on and put all your eggs on. Those are not the
eggs you want to put in one basket, particularly when the
range in the sed rate is so small. I mean, there was a point
when she was already on 40, and 1 thought, We are going on
the right path. She is down on her prednisone. Her sed rate
goes to 28 and he says, Oops, it went up to 28. Let's jump
to 60 milligrams. That almost shocked me when I read it.
That's the last thing you would do.
Then the CPK. Following the CPK is not so simple
either. CPK or the creatinine phosphokinase, a muscle
enzyme, in people as heavy as she is, even before she gained
nearly 100 pounds, is not as reliable a marker. People that
have rhabdomyolysis - she has already demonstrated that her
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"recent" means the past six or seven years. Before that we
didn't have troponins and we relied on CPK for diagnosing a
heart attack.
Q. Do you know if the CPK was fractionated in this
case?
A. It was never fractionated. And people like
Ms. Munson, they can have a kind of high CPK just from the
stress that their muscles are taking because of weight. We
know that it's unlikely for somebody her age and just about
her fascial plastic surgery to have such a high CPK. She has
some susceptibility in her muscles from the recent high
enzymes, so that becomes an unreliable monitor of how you ard
doing. Plus the labs for CPK normals vary like crazy. And
so what you call high CPK one day is not high the next
because of the lack of transient parameters.
Except for that one time when she has the rhabdo,
she had very, very minimal CPK elevations, if any. Most of
them were within the normal range. And CPK, again, is
affected by prednisone. So prednisone has this kind of
paradoxical effect on CPK. Even though it can cause a
myopathy ~ prednisone itself can cause muscle symptoms
similar to what she has got. It still will reduce the CPK to
the extent where you say, Hmm, the enzymes are getting
better.
You can't measure the enzymes and determine how well
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1 you are doing with polymyositis. 90 percent of it really
2 depends upon - and this is when you have a firm diagnosis.
3 90 percent of it depends upon the clinical response. It's
4 not so hard because in polymyositis it isn't just subjective.
5 "Clinical" doesn't mean just subjective. How are you feeling
6 today? Oh, terrible. Why? Because my girlfriend and I had
7 a fight. It's not how you are feeling. It's, How do you
8 feel to me? You actually squeeze muscles. You touch
9 muscles. You examine muscles. These muscles are abnormal.
10 You feel your own muscle and you feel a patient's muscle with,
11 polymyositis and say, Wow, there is a difference. The muscle
12 is red, it's warm, and sometimes it's hot to the touch. It
\
13 hurts like the dickens. It has a different consistency.
i
14
Q. Do they get hard?
15
A. Sometimes they get soft and sometimes they get hard.
16 Earlier in the course of the disease, actually sometimes they
17 are quite soft because they are inflamed.
I
18
Q. I know at one point she had complained of her
19 muscles being hard to the touch.
20
A. The problem with hard is that muscle spasm feels
21 hard. A charley horse makes it feel hard. You can't really
22 hang your diagnosis on that, but a charley horse would never
23 feel warm to the touch, like inflamed, and a charley horse
24 actually feels better if you squeeze it. Polymyositis, it
25 hurts like the dickens when you squeeze it.
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the diagnosis and the possible outcome of prednisone
treatment at high doses." Again, your understanding that she
wasn't told about these comes from the absence of information
in the medical records that you've seen?
A. Right.
Q. I understand you haven't reviewed Dr. Chamberlain's
deposition testimony, but that Mr. Parkinson told you a
little bit about it at lunch today.
A. Yes.
Q. Did he give you any information about the consent or
Dr. Chamberlain's testimony about consent?
A. He just kind of briefly mentioned in passing that
Dr. Chamberlain says, Yes, he warned her, and that the
patient says, No, he didn't.
Q. When you mention the "tenuous situation" of the
diagnosis, is that what you referred to earlier in terms of
telling the patient explicitly, you know, We're working with
this diagnosis but we are not certain of it?
A. In fact, the form was critical criteria for the
diagnosis, the clinical presentation. The absence of a
positive EMG, a normal biopsy, and the lack of appropriate
enzyme elevation.
Q. The normal biopsy, you said?
A. Right. Normal muscle biopsy.
Q. It seems like the biopsy needed to have been of a
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One of my patients with active polymyositis started
missing appointments because she said, It just hurts too much
when you examine my muscles. And as gentle as you try and
be, it actually hurts them. She had a big problem with
marital relations because her muscles just hurt too much, so
I had to have a conference with her and her husband and
explain, Hey, this isn't because she doesn't love you
anymore, this is because it's part of her disease process.
MR. PARKINSON: Counsel, while he was going through
his discussion, there was someone who brought in select
copies. Are we going to mark that as an exhibit?
MS. SHERMAN: Yes. I need to get other copies made,
so when we take another break, I'll have them make a copy for
you.
MR. PARKINSON: Some of those documents I haven't
seen myself, so if we make it an exhibit, I don't really
care. You don't have to make a separate copy for me if we're
going to make it an exhibit. I have no problem with that.
Otherwise, 1 would like copies.
MS. SHERMAN: All right.
MR. PARKINSON: Thanks.
Q. (BY MS. SHERMAN) Again, looking at the second half
of page 2 of your opinion, the paragraph numbered 2, it's the
second paragraph numbered 2 on that page, it says, "Informed
Consent. Rebekah Munson was not told of tenuous situation of
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proximal muscle?
A. Well, because polymyositis is a disease mostly
affecting proximal muscles, you would think that's where you
go for the biopsy. But the truth is, since it has "skip"
areas, you go where the symptoms are. And I'm assuming they
biopsied where her symptoms are; otherwise, why didn't they
just do a hair biopsy? It's a lot less painful.
Q. So the fact that it was a normal biopsy when they
did it — my understanding is the biopsy was of a distal
muscle rather than a proximal muscle?
A. It was her calf as opposed to her thigh or her
hamstring.
Q. So distal is further from the trunk and proximal is
closer?
A. Right.
Q. It's also my understanding that they did it in the
calf because that's where she claimed that it hurt. In those
circumstances where the biopsy was distal but normal, does
that rule out satisfaction of that one clinical element?
A. Correct. You can't base your diagnosis on a
negative biopsy. It's true if we're looking for cancer of
the colon we biopsy it. If we biopsy the wrong place, you
don't say, Okay, you've got it; you've got cancer ~ because
we biopsied the wrong place.
Q. But in polymyositis, the biopsy would show -- what
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would it show?
A. If it were positive?
Q. Yes.
A. It would show the infiltration of white blood cells,
primarily lymphocytes. It would show polymorphonuclear cells
as well. It would show swelling of the membranes, the
vessels and the muscles. It would show the muscle actually
thickened and edematous with fluid. It would show some
muscle cells in the state of complete deterioration as though
they are being dissolved. It would show other muscles where
the healing process has tried to take place with some
scarring of connective tissue.
A biopsy is the gold standard for diagnosis of
polymyositis. If for no other reason, it helps you separate
a dozen other diseases that can implicate and simulate
polymyositis. Even muscular dystrophy can look like
polymyositis -- to show you what a severe disease it is. But
the biopsy is the standard answer.
Q. But the fact that the biopsy was negative, standing
alone, doesn't rule out a diagnosis of polymyositis?
A. No, of course not. If you biopsy the wrong place or
even the right place, but you just happen to miss it. Don't
forget muscle biopsies are generally very, very small pieces.
You don't remove a whole muscle to assess it. You have to
hit it right. Your chances improve by going where they hurt,
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diagnosis before you say to this patient, I know you are
going to gain 50, 70, 100 pounds, but it's worth it;
otherwise, you will never get over this disease. And the
patient makes an informed consent. Well, let's see; do I
want to live another ten years and be thin and svelte and
what's considered by society to be beautiful, or do I - it's
either-or. It can't be both - or, Am I willing to take
medications and gain 100 pounds but live another ten years?
Q. The weight gain one gets with steroids, is that
limited to the duration of the course of treatment with the
steroids? Is it possible to lose the weight afterwards?
A. Well, in theory that's true. To some extent that's
what happened with Ms. Munson. After she was taken off the
prednisone, she went back. Now, I think she still weighs in
the 250 range, but she is no longer 330.
Q. Presently, you mean?
A. Yeah. From personal experience, I'll tell you, it's
always easier to gain than to lose. And even when the gain
is artificial or stimulated by some exogenous agent like
prednisone, the fact that, Don't worry, honey, you will lose
all this weight when I get you off prednisone - is not
100 percent. You lose most of it. That weight that was
gained purely because of a fluid buildup, you lose. That's
the weight that was gained because of fat accumulation, and
prednisone causes fat accumulation. It causes your
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and your chances are improved if you have 20 or 30 or 40
biopsies. Obviously your results are going to be much mord
reliable.
The percentage of getting it wrong decreases with
the biopsy, but that's not - you know, patients aren't going
to subject themselves to that kind of abuse. That's why
we have tests like an EMG. An EMG is almost harmless. Ifl
may be a little uncomfortable, but it's certainly not like a
biopsy. And that also is very, very helpful in
differentiating all the things that look like, smell like,
taste like polymyositis, but are not.
Now, if the treatment were Tylenol for both, you
wouldn't even have to subject her to an EMG because it
doesn't matter. The treatment is pretty harmless and it's
the same for it. But when you've got treatment that's
fraught with problems, you want to be certain of the
diagnosis.
1 think my example of cancer is a perfect one. You
would never give somebody chemotherapy before you had a
tissue diagnosis, right? You go through extreme lengths to
do biopsies. You do laparotomies. You open up a patient's
entire gut to look for that cancer before you make the
diagnosis and treat them.
The same thing pertains to polymyositis. You have
got to go to whatever length it takes to confirm that
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metabolism of sugar to change so that you are storing fat
instead of burning fat.
That's what causes diabetes. That's why it causes
elevations in the blood pressure. That's why it causes
myocardial problems. That's why it causes ~ I mean, it has
mineralo and glucocorticoid effects, two separate things that
prednisone does, and those affect in one fashion or another
almost every organ in the body.
Q. What side effects of the prednisone did Ms. Munson
experience in this case?
A. Hypertension; obesity; steatosis was diagnosed,
which is fatty liver infiltration; depression. Some of these
diagnoses notwithstanding were present beforehand, but I
think were aggravated during the course of the treatment,
even by Dr. — well, actually, I don't remember which
physician, but several of the physicians who saw her at that
point stated that there was an aggravation.
Q. At which point?
A. After she was on steroids — after July. I think
Dr. Chamberlain himself stated she had weakness and fatigue,
she had edema, which was swelling from fluid, headaches,
blood sugar - by September of'99,1 think it rose to 121.
By today's definition, that's diabetes. She developed
paresthesias, numbness and tingling in the digits. She
developed frequent infections, both vaginally with yeast, and
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I think she developed a sinus infection too.
In fact, at one point Dr. Chamberlain thought maybe
this whole thing is some deep-rooted infection which we
haven't identified, and he said, Let me put her on some
antibiotics empirically without having a confirmed diagnosis.
But at least with antibiotics, provided you are not allergic,
you take them for ten days and then you are done. So if
there was no infection, you really haven't lost much. It's a
good diagnostic tool.
But he even then said — I think in that note
sometime in - I don't know if it was in March or April. No,
it must have been April. It was sometime in August. I think
he said, If this doesn't make you better, we should seek
consultation.
Getting back to her symptoms, she developed
amenorrhea, she stopped having menstrual periods, and
sometimes steroids at this dose at this length causes
polycystic changes, what we call Syndrome X or dyslipidemia.
I don't know if you are familiar with that.
Q. I am not.
A. It causes weight gain, hypertension, diabetes,
elevated cholesterol and triglycerides. Or recently the
syndrome which leads to coronary artery disease, kidney
failure and strokes has been tied to a disease called
"polycystic ovary disease." And prednisone, things that make
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Q. That's what you mean by "not prepared"?
A. Right.
Q. You mention at the end of paragraph 5 that
Dr. Chamberlain should have considered alternative treatment.
A. Yes.
Q. What alternative treatment should he have
considered?
A. Voltaren, that's a nonsteroidal anti-inflammatory
agent, which she herself told him she felt better on than
with prednisone, but that she couldn't afford it. Now, the
makers of Voltaren - I forgot which pharmaceutical it is they have a program where they will provide to a patient who
is indigent and needs it free of charge. I don't know if
that was true then. I know it's true now.
Many of the pharmaceuticals have a program where
they will simply at the request of the physician provide the
patient with the drug they need when they can't afford it and
it happens to be the only one in that class that helps them.
So there is an alternative right there. She felt better with
a simple nonsteroidal anti-inflammatory agent than she did
with prednisone. There is an alternative.
If the Voltaren wouldn't have sustained her
improvement, I guess I might even — and if he felt strongly
about the diagnosis of polymyositis, and he says, You know, I
don't care what the biopsy shows and what the EMG shows. I
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you gain weight, sometimes cause your ovaries to undergo
1 don't care what the enzymes say, I'm convinced that's what
polycystic changes. I don't know that she has that. I'm not
2 you've got If you are willing to bear with me on this, I
saying that she suffered that.
3 would like to try you on low-dose methotrexate. That's a
She did have, however, gallbladder disease, which is
4 reasonable consideration. I would like to try you on some
a known complication of steroid therapy and obesity, and
5 sort of behavioral therapies. Let's get you to see a
cataracts. Now, there was a question whether she had
6 psychiatrist. Maybe the reason you are not responding to
cataracts or not, but I never saw the final ophthalmologic^
7 medication is because you are so upset, and prednisone
evaluation. She had heartburn and GI symptoms, dyspepsia and
8 aggravates, you know, your psychiatric status. There are so
gastroesophageal reflux disease, which are common even with
9 many other options.
low and short-course doses of steroids, but certainly
10
My own personal option just from reviewing this
high-dose, long-course treatment. I think we mentioned
11 record is - and I just want to reiterate, I have never seen
depression. These are all things that I think she had either
12 this patient except in pictures.
de novo or aggravated by steroid treatment.
13
But my own view would have been, Let's stop all your
Q. In paragraph 3, returning to your opinion, you state
14 treatment; let's give your body a chance to heal from all the
that, "Diagnosis of polymyositis was tenuous at best.
15 damage of the prednisone, and for that matter, the
Rebekah Munson was not prepared for," and then you list some 16 nonsteroidal anti-inflammatories — because, you know, they
of these symptoms that we just discussed — or some of the
17 have got mineralo and glucocorticoid effects too; they are
side effects, rather, that we just discussed. Is the
18 just not as severe as steroids; let's get you off of
criticism of Dr. Chamberlain's treatment expressed in
19 everything and see what happens; let's get you in a good diet
paragraph 3 sort of a further articulation of your criticism
20 and good exercise program.
of his informed consent?
21
Because even losing a little bit of weight, even 10
A. Yes. I think there is a — it's more. The informed
22 percent of your body, or let's say 5 percent, a 15-pound
consent is simply that he didn't give it to her. Here 1 am
23 weight loss would have made her feel so much better. We knowj
stating that if she were given the option, she might choose
24 it would have improved her glucose. It would have improved
not to go with the treatment.
25 everything. The strain and stress on her muscles, the ease
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with which her heart functioned, all those things would have
been better.
So my approach would have been, Let's get you off
all these medications because they all have side effects. At
the very least what would have happened then is I think he
would have said to himself, We've still got a problem. She
has still got symptoms. I've gotten her off all of her
medications, but now it's back to being a virgin case.
We have a fresh look. Let's do an HLA B-27. Let's do a sed
rate because we don't have meds that are murking the picture.
Let's now do a CPK, but aldolase. Let's look at her SGOT,
SGDT. Those are technically called liver enzymes, but they
are muscle enzymes as well. Let's do another muscle biopsy.
Let's go proximal this time. Let's repeat the EMG. Maybe
the steroids interfered with the EMG.
If all that fails and I can't come up with a
diagnosis, I am going to talk to my favorite rheumatologist,
who I send a lot of cases and he owes me some favors, and he
is going to see you free of charge. Or let's get my office
manager to help get you Medicaid or some sort of welfare
benefit or somehow to arrange for a payment plan so a
rheumatologist can see you and help me nail down this
diagnosis so I can make you feel better. That's what I would
have done.
Q. In the last paragraph of your opinion you state that
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aggravated and required a gallbladder removal in a patient
who was on steroids. I think it's one of the things we list
on the informed consent, of which I think you probably made a
copy.
Q. Yes, I did. Those informed consents that were in
your file —
A. There were three different ones.
Q. Are those ones that you use in your practice or ones
that you got —
A. I will show you which one 1 use. It's kind of one I
tailor-made and I find most comprehensive.
MR. PARKINSON: I haven't seen those documents.
MS. SHERMAN: I'll get copies made for you after,
Ken, if you would like.
THE DEPONENT: This is the one I have kind of put
together because I think it's the most fair. 1 think from
this the patient will pretty much see what could happen and
allow the patient to make a real reasonable decision.
Q. (BY MS. SHERMAN) Could you just identify which one
that is. What does it say at the top?
A. It's the one that says "Corticosteroid Consent
Form," and the first line above states, "Because of the
severity of your disease, your physician" — I guess because
I've given this to a number of my compatriots and certainly
my associates in the office, I didn't stick my name on it.
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"Proper treatment in accordance with the standard of care
would almost certainly have led to a correct diagnosis and
proper treatment and would have saved Rebekah Munson from
additional health problems and side effects associated with
prednisone use." When you refer to the additional problems
and side effects, is that in addition to those side effects
listed in paragraph 3 or —
A. It refers mostly to those in 3, but the list I gave
you may have included additional things. I didn't list the
gallbladder problem, I didn't list the cataracts, although I
alluded to visual disturbance. I don't think I listed
gastroesophageal reflux disease. So there are additional
factors, but they are all contained in my answer about what I
think she suffered from as a consequence of prednisone.
Q. She had a - and I always stumble over the
pronunciation of this word. It's the removal of the
gallbladder.
A. Cholecystectomy.
Q. Is it your opinion that that was necessitated by the
steroid treatment?
A. We know that gallbladder disease is affected by
weight and steroids and pregnancy, and part of the reason
it's affected by pregnancy is because of this hormonal shift
of which prednisone takes part as well. So, yes, 1 think so.
I myself have probably had eight or nine cases that
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It says, "your physician feels that the corticosteroids are
indicators and part of your treatment."
Q. Then you have another consent form headed "Patient
Consent For Corticosteroid Therapy." Is this also one that
you prepared or one you received from another source?
A. This one I think came from the risk management
department at Copic Insurance Company. I think that's the
largest Colorado malpractice carrier. I think you will find
a lot of similarities here, as a matter of fact. And the one
that was recommended even years ago but was very, very basic
just says, Look, you can get thinning of the bones and
osteoporosis, fractures; you can get loss of blood to the
bones, which requires surgical correction.
Actually, that's an aseptic necrosis, which is still
a problem today from heavy uses of steroids in asthmatic
patients with use of lots of steroids when they young. High
blood pressure, increased pressure in the eye, that's
glaucoma and cataracts. But nowadays that's probably not
enough. That's the opinion we have from lawyers like you and
you, you know, that we really need to give the patients a
fairer notion of what they can expect with corticosteroid
treatment.
Q. I just have a few more questions to wrap up. I'm
going to refer to some of the allegations that the plaintiff
made in her complaint. As I understand it, you have not
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reviewed the complaint; is that true?
A. I think that's correct, yes. I have not.
Q. The plaintiff contends in her complaint that
Dr. Chamberlain incorrectly diagnosed Ms. Munson's condition.
Do you agree with that statement?
A. Yes.
Q. The plaintiff also contends that Dr. Chamberlain
incorrectly prescribed prednisone considering the plaintiffs
condition. We have discussed that. The plaintiff also
contends that Dr. Chamberlain failed to consider the prior
test that had been performed.
A. I guess that depends on what she is referring to, so
1 can't comment on that. We talked about the testing, the
EMG. We talked about testing of her enzymes and
sedimentation rate. We talked about testing of her muscle
biopsy. If that's what she is referring to, then I would
agree, because those are all strong factors that point away
from the diagnosis of polymyositis.
Q. Do you intend to offer criticisms of anyone else in
this case?
A. I don't know of anyone else in this case.
Q. You mentioned briefly the Rheumatology Primer and
the Harrison's Internal Medicine texts. Can you think of any
other authoritative treatises or publications that one could
refer to?
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bunch. Plus your favorite medical school or hospital
librarian will help you. You call them up and you say,
Please give me all the articles in the past three years on
current developments in any disease. And within a couple of
days you have reams and reams of pages, just summaries,
synopses, and then you read this and say, This is the one I
want to read. Boy, this age of information has made it tough
to remain a good doctor.
Q. There is plenty of information out there.
A. I think too much.
Q. Do you contemplate doing any additional work to
corroborate or test your opinion?
A. Only if asked to do so. By that I mean ~ like, 1
have not reviewed depositions and 1 have not reviewed ~ I
was just handed a piece of paper that - I don't know if it
was like some specialist's opinion that everything in this
case was perfect.
MR. PARKINSON: It's your expert's opinion.
THE DEPONENT: It wasn't even that strong. He just
said, Well, it's okay. It wasn't perfect. So I haven't
reviewed any of that stuff in detail and really hope I don't
get asked to.
Q. (BY MS. SHERMAN) Have you now told me all the bases
for your opinions?
A. Yes.
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A. There are hundreds.
Q. The best among those are the ones you have already
consulted?
A. Well, Harrison's ~ I don't know if I would call it
the best. It's the most standard. It's the bible. It's the
standard volume of medicine for internal medicine. It's the
only book of its kind - it's one of two books of its kind
where it really goes into detail about almost every disease
known to man. The primer is great because it gives you a
focus on the rheumatologic diseases.
Today, in this day and age when I get asked, Well,
what's the best source of information? I say, The Internet.
It's wonderful because it gives you current publications and
it gives you summaries. It gives you a whole idea about the
state of the art, what's going on. And although I have vowed
never to become computer literate, I pretty much have to just
to stay current on some of this stuff, because the computer
has got it on there before it's even published.
Q. Which Internet sources do you rely on?
A. A dozen or more on my favorite sites.
Q. Can you think of—
A. Merck has one, Index Medicus. And, of course, they
cross-reference each other. I mean, I have a whole number of
them, but they will frequently refer to the same sources. So
1 don't know if there is an advantage of having a whole
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Q. Thank you for coming, Dr. Jacobs.
MR. PARKINSON: I have a statement and then a couple
of brief questions. First, I probably will have him read the
deposition prior to trial, but 1 don't anticipate that that
will change his opinion, but I will probably provide that to
him.
EXAMINATION
BY MR. PARKINSON:
Q. If in treating a person who you diagnosis with
polymyositis, if you were dissatisfied with the biopsy
location that was taken, what's the appropriate way to deal
with that problem?
A. Let's repeat the biopsy and do it in an appropriate
place.
Q. You stated that you provided no opinions about the
negligence of Central Utah Medical Clinic. You are not
stating a legal opinion there about whether Central Utah
Medical Clinic has any responsibility for Dr. Chamberlain,
are you?
A. That's correct. I wouldn't be aware of any legal
issue here.
MR. PARKINSON: I have no further questions.
WHEREUPON, the within proceedings were concluded
at the approximate hour of 4:35 p.m. on the 18th day of
November, 2002.
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REPORTER'S CERTIFICATE
STATE OF COLORADO)
) ss.
COUNTY OF DENVER)
I, Marchelle Hartwig, Certified Shorthand Reporter
and Notary Public, State of Colorado, do hereby certify that
previous to the commencement of the examination, the said
ALEXANDER JACOBS, M.D. was duly sworn by me to testify to the
truth in relation to the matters in controversy between the
parties hereto; that the said deposition was taken in machine
shorthand by me at the time and place aforesaid and was
thereafter reduced to typewritten form, consisting of 74
pages herein; that the foregoing is a true transcript of the
questions asked, testimony given, and proceedings had.
I further certify that I am not employed by,
related to, nor counsel for any of the parties herein, nor
otherwise interested in the outcome of this litigation.
IN WITNESS WHEREOF, I have affixed my signature
this 5th day of December, 2002.
My commission expires 4/19/05.
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REPORTER'S CERTIFICATE
STATE OF COLORADO)
)
COUNTY OF DENVER )

ss.

I, Marchelle Hartwig, Certified Shorthand Reporter
and Notary Public, State of Colorado, do hereby certify that
previous to the commencement of the examination, the said
ALEXANDER JACOBS, M.D. was duly sworn by me to testify to the
truth in relation to the matters in controversy between the
parties hereto; that the said deposition was taken in machine
shorthand by me at the time and place aforesaid and was
thereafter reduced to typewritten form, consisting of 74
pages herein; that the foregoing is a true transcript of the
questions asked, testimony given, and proceedings had.
I further certify that I am not employed by,
related to, nor counsel for any of the parties herein, nor
otherwise interested in the outcome of this litigation.
IN WITNESS WHEREOF, I have affixed my signature
this 5^ day of December, 2002.
My commission expires 4/19/05.

Marchelle Hartwig, CSR
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Your partner in making the record
Court Reporting & Video

HUNTER&
GEISXINC

December 5, 2002

ALexander Jacobs, M.D.
3300 East 17th Avenue
Denver, Colorado 80206
Re:

Rebekah Munson v. Bruce H. Chamberlain, et al.

Dear Dr. Jacobs:
Enclosed you will find a complimentary copy of your
deposition taken in the above matter. Also enclosed are the
original signature page and amendment sheets for your
deposition.
Please read the transcript, make any corrections on the
amendment sheets, and sign the signature page and
amendment sheets before a notary public. After you have read
and signed your deposition, please forward everything back to
my office in the enclosed envelope within 30 days from the
date of this letter.
Sincerely,

i

Marchelle Hartwig
HUNTER k GEIST, INC.
Registered Professional Reporters
c:

Tawni J. Sherman, Esq.
Kenneth Parkinson, Esq.
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DR- ALEXANDER JACOBS
EXPERT WITNESS REPORT
June 5, 2002

I am a physician practicing internal medicine full time. I am board certified in internal
medicine. My credentials are set forth in the curriculum vitae attached as Exhibit "B" to my
report.
I have reviewed the following medical records pertinent to the care of Rebekah Munson:
A.

Medical records of Dr. Richard Call

B.

Medical records of Dr. Bruce Chamberlain and Central Utah Medical Clinic

C.

Medical records of Dr. Richard Gremillion

D.

Medical records of Dr. Richard Rosenthal

E.

Medical records of Dr. Joseph Watkins

F.

Medical records of Dr. Doug Jones

G.

Medical records from Utah Valley Regional Medical Center for emergency room
visit of 12/18/98

The important facts which I have discovered from the medical records and which I have
used to form my opinions are as follows:
1.

Prednisone was given as early as 1998, post plastic-surgery for a short course. It

helped temporarily and was then discontinued. Prednisone was reinstated a second time in
approximately July, 1999 and it did not help even though it was pressed to high doses: 60 mg
for five months, followed by 50 mg for ten days, followed by 40 mg for another month and by
January 25, 2000 when Ms. Munson finally sees Dr. Gremillion, he tapers her to 30 mg then 20
mg and ultimately gets her off Prednisone and replaces treatment with nonsteroidals,
Digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, BYU.
Machine-generated OCR, may contain errors.

methotrexate.
2.

Muscle biopsy performed on March 19, 1999 is negative showing no evidence of

myositis. EMG is completely negative. No evidence of myopathy or neuropathy.
3.

Dr. Chamberlain questions the diagnosis of polymyositis, indeed putting a ? after

that term, however, he continues to treat with prednisone.
4.

When the sed rate is 57 on July 19, 1999 and the rest of the labs are normal, Dr.

Chamberlain states, "lets look for hidden infection", ie: looking for another infection/explanation
for symptoms, however this is not done.
5.

Dr. Chamberlain opined as early as March 26, 1999, that he might need a

rheumatologic consultation, however one was not done until January of 2000. After the
appointment with the rheumatologist the diagnosis was changed and ultimately Prednisone was
tapered and discontinued.
6.

On February 10, 2000, a diagnosis by Dr. Gremillion is made of spondylitis with

SI joint inflammation. Subsequently the original symptoms improve.
The standard of care was breached by Dr. Richard Chamberlain for the following reasons:
1.

Prednisone therapeutic trial should last a week, two weeks or at the most three

weeks, but if no improvement, one must challenge and question the diagnosis and certainly the
treatment.
2.

Informed Consent. Rebekah Munson was not told of the tenuous situation of the

diagnosis and the possible outcome of Prednisone treatment at high doses.
3.

Diagnosis of polymyositis was tenuous at best. Rebekah Munson was not prepared

for the elevated blood sugar, elevated white count, elevated weight, elevated blood pressure,
increased depression and dysphoria, yeast infections, headaches, visual symptoms, shortness of
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breath, edema, heartburn, diarrhea, bruising and polydypsia.
4.

When treatment fails or side-effects become quite profound, prudent rule is to

consider new diagnosis, new treatment and seek consultation.
5.

Even if Rebekah's diagnosis was such that it required Prednisone, when it failed

to do much good from a symptomatic standpoint and all of the side-effects were noted, Dr.
Chamberlain should have considered alternative treatment.
Proper treatment in accordance with the standard of care would almost certainly have led
to a correct diagnosis and proper treatment and would have saved Rebekah Munson from
additional health problems and side-effects associated with Prednisone use.
DATED this

/~7 day of June, 2002.

ALEXANDER JACOBS, AID., INTERNAL MEDICINE

J-VKBPUACOBSJLE?
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